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Résumé
Des émulsions furtives ont été préparées à l’aide d’excipients approuvés pour
une application pharmaceutique et ont été évaluées in vivo pour leur capacité à cibler
des tissus néoplasiques. Les émulsions étaient composées d’une phase interne de
triglycéride et émulsifiées avec un tensioactif synthétique (polysorbate 80) et un co
émulsifiant lipidique. Afin de produire des émulsions furtives, de la sphingomyéline
d’oeuf (ESM) a été choisie comme co-émulsifiant et différents dérivés de 1,2-
distéaryl-sn-glycero-3 -phosphatidyléthanolamine-poly(éthylène glycol) (DSPE-PEG)
ont été greffés à l’interface de l’émulsion. Les dérivés sélectionnés de DSPE-PEG
étaient la DSPE-PEG 2000, la DSPE-PEG 5000, et la DSPE-N-{pentaérythritol
polyoxyéthylène glutaryl] (DSPE-4armPEG), (MM 2000). Les effets de l’ESM et de
la DSPE-PEG (la concentration et la structure) sur la prolongation du temps de
circulation et sur l’accroissement de l’accumulation dans les tissus néoplasiques ont
été évalués sur des souris inoculées du mélanome B16 et de l’adénocarcinome du
côlon C26 en sous-cutané.
Dans cette étude, nous rapportons que des émulsions furtives ont été obtenues
en enrobant la surface des gouttelettes avec de la DSPE-PEG 2000 ou 5000.
L’accroissement du temps de circulation n’a pu être atteint ni avec la DSPE-4-
armPEG malgré le segment de PEG de masse molaire de 2000 ni avec l’ESM. Le
temps de circulation accru des émulsions enrobées de PEG 2000 ou 5000 s’est traduit
par une accumulation plus élevée dans les tumeurs C26, mais pas dans les tumeurs
B16. Ces émulsions pouvaient améliorer la sélectivité d’agents anticancéreux
111
lipophiles pour certains tissus néoplasiques et aussi augmenter leur index
thérapeutique.
Mots-clés : Émulsions furtives, poly(éthylène glycol), biodistribution,
pharmacocinétique, vecteurs de médicaments
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Abstract
Long-circulating emulsions were prepared using pharmaceutically acceptable
excipients and evaluated in vivo for their ability to target neoplastic tissues. The
emulsions were composed of a triglyceride internai phase and emulsified with a
synthetic surfactant (polysorbate $0) and a lipid emulsifier. Attempts made to produce
long-circulating emulsions included adding egg sphingomyetin (ESM) as a
coemulsifier and graffing various 1 ,2-distearoyl-sn-glycero-3-
phosphatidylethanolamine-poly(ethylene glycol) (D$PE-PEG) derivatives into the
emulsion interface. The DSPE-PEG derivatives selected were D$PE-PEG 2000,
DSPE-PEG 5000 and DSPE-N-[pentaerythritol polyoxyethylene) glutaryl] (D$PE-4-
armPEG), (MW 2000). The effect of ESM and DSPE-PEG concentration and
structure in prolonging circulation time and enhancing accumulation into neoplastic
tissues was assessed in mice bearing subcutaneously implanted B 16 melanoma or
C26 colon adenocarcinoma.
In this study, we report that long-circulating emulsions were obtained by
coating the droplet surface with single chain DSPE-PEG 2000 or 5000. Circulation
Ïongevity could flot be achieved with DSPE-4-armPEG despite the 2000 MW PEG
segment nor with ESM. Enhanced circulation time of emulsions grafted with PEG
2000 or 5000 translated into higher accumulation into C26 tumors but flot into B16.
These emulsions can potentially enhance the specificity of lipophilic anticancer drugs
towards neoplastic tissues and enhance the therapeutic index.
Keywords: Long-circulating emulsions, poly(ethylene glycol), biodistribution,
pharmacokinetics, drug carriers
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1CHAPTER 1: COLLOIDAL DRUG CARRIERS
21. Introduction
Conventional, low-molecular weight therapeutics ofien have the ability to
traverse across various biological membranes and compartments, showing littie or no
selectivity for diseased tissues over healthy ones [1]. This poor specfficity for the
target site ofien leads to undesirable side-effects and low proportions of the
administered dose reaching the intended site of action in the body. As a resuit, higher
doses ofien need to be administered to achieve therapeutic concentrations at the target
site. To circumvent this non-specific drug delivery, substantial efforts have been
made to alter the pharmacokinetic and tissue distribution of drugs by incorporating or
attaching them to colloïdal systems such as liposomes, micelles, macromolecular
prodrugs, polymeric nanoparticles, and emulsions. By including or linking them to
colloidal carriers the distribution of the therapeutic agent no longer depends on the
physicochemical properties of the drug molecule but instead is contingent on the
features ofthe carrier.
One way in which colloids achieve selectivity is a resuit of their large size
which restricts extravasation to locations in the body with permeable vasculature (see
figure 1). Solid tumors and sites of infection or inflammation ofien have porous
blood capillaries, which allow for the passage of nano-sized colloidal drug carrier
across the endothelium and into the extravascular space (passive targeting). Given
that the majority of the vascular endothelium is continuous with tight junctions
between neighboring endothelial ceils, active compounds associated with colloïdal
carriers are prevented from reaching the extravascular space of most tissues in the
body reducing many ofthe adverse side effects caused by drugs in the free form [2].
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figure 1: Capillary structure of normal tissues with a continuous endothelial lining
(A) and tumors possessing enhanced vascular permeability (B).
4In addition to the selectivity imparted by size, targeting moieties that are specific for
determinants found primarily or in high amounts on the membrane of target celis can
be attached to the surface ofthe carrier to enhance specificity (active targeting).
Another application of colloids is in the controlled release of therapeutics,
whereby they act as reservoirs that release the encapsulated drug into the blood
stream slowly. Such sustained release systems can maintain therapeutic drug levels in
the blood, reducing the frequency of administration. Furthermore, colloidal drug
delivery systems can also overcome efflux pumps such as P-glycoprotein (Pgp) by
changing the pathway in which drugs enter the ceil. Intracellular intemalization of
colloids by endocytosis Iocates the drug in an endosome/lysosome, which reduces
interactions with Pgp compared to drugs in the free form that traverse across the ceil
membrane by diffusion [3]. Other advantages of colloidal drug delivery systems
include protection of the encapsulated drug from premature degradation and enhanced
intracellular delivery of certain therapeutic compounds. For instance, free or un
encapsulated genetic material requires a carrier to enter the ceil because of the
unfavorable electrostatic interactions between DNA and ceil membranes.
Depending on their size and the physicochemical properties of the surface,
colloids can be rapidly taken up by the ceils of the mononuclear phagocyte system
(MPS) and quickly removed from the systemic circulation. Such systems are ideal for
macrophage targeting. On the other hand, colloids can exhibit long-circulating
properties in blood and target sites in the body other than MPS tissues.
Indeed, colloidal drug delivery systems offer many benefits over drugs in the
free form. These systems, however, vary in terms of physicochemical properties and
5thus have different advantages and drawbacks. An overview of the most common
colloidal drug delivery systems is briefly presented in the following sections.
2. Liposomes
Among the various colloidal drug delivery systems investigated, liposomes
are the most widely studied. They can be formed from either synthetic lipids or lipids
originating from biological membranes. Liposomes typically range in size from 50 —
10,000 nm and are classified as either small unilamellar vesicles (SUVs), large
unilamellar vesicles (LUVs) or multilamellar vesicles (MLV5). LUVs have diameters
usually between 100 to 500 nm and are bigger than SUVs [4]. They are composed of
an aqueous muer core surrounded by a single lipid bilayer. In contrast, MLVs contain
several concentric lipid bilayers and vary in size from 100 to 10,000 nm [4]. These
unique structures permit the encapsulation of either hydrophilic or hydrophobic
compounds. The behavior of these systems in the host depends largeÏy on size,
bilayer rigidity and surface charge [5, 6].
Based on composition and therapeutic application, liposomes are generally
categorized into 4 major types which are conventional, ‘stealth’ or long-circulating,
immunoliposomes (targeted), and cationic liposomes [7]. Conventional liposomes are
usually quickly removed from the systemic circulation by the MP$ and thus are more
appropriate for macrophage targeting, local depot or antigen delivery (vaccination)
[7]. Conversely, ‘stealth’ or long-circulating liposomes evade detection by the MPS
and tend to extravasate into tissues with enhanced vascular permeability (i.e. solids
tumors and sites of infection or inflammation) [8-10]. The most widely used method
to produce liposomes with enhanced blood residence times is to coat the surface of
6the carrier with poly(ethylene glycol) (PEG). This polymer provides long-circulating
properties by reducing interactions with plasma proteins and ceil surfaces because of
its highly hydrated and flexible polymer chains [1 1, 12].
The specificity of encapsulated drugs towards the intended location can be
enhanced by attaching ligands such as antibodies, antibody fragments, peptides,
carbohydrates, vitamins or hormones onto the surface of the carrier that are specific
for certain sites on the membrane oftarget celis [13]. If the encapsulated drug is to be
delivered to non-MPS tissues, PEG can be grafied onto the surface of the liposome
along with the targeting ligands to reduce uptake by macrophages [14]. Apart from
being carriers for conventional drugs, cationic liposome complexes are being
developed to protect genetic material (e.g. DNA and RNA) from degradation in the
blood stream and enhance transfection into the celI [15].
As a resuit of the large effort in developing liposomes as drug delivery
vehicles, several liposome formulations are presently on the market, such as
Doxil®/CaelyxTM, Myocet®, DepoCyt®, and AmBisome®, just to name a few [16].
Liposomal products currently on the market offer treatment for a wide range of
illnesses including cancer, Kaposi’s sarcoma, ftmgal infections, and meningitis.
Despite the many advantages of liposomal drug delivery systems there are
several drawbacks, which include poor efficiency to load hydrophobic moÏecules as a
result ofthe limited solubility in the lipid bilayer and poor stability during storage due
to hydrolysis and/or oxidation of the lipids in the bilayer. Formulation stability can be
improved by preparing the liposomes with saturated lipids and displacing the air with
an inert gas such as argon.
73. Micelles
Micelles are core-sheÏl structures formed from amphiphilic molecules such as
low-molecular weight surfactants or block copolymers. These amphiphilic molecules
self-assemble in aqueous solvents at concentrations above the critical micelle
concentration (CMC). The hydrophobic core provides a cargo space for poorly-water
soluble compounds, while the hydrophilic corona permits solubilization in aqueous
media [17]. As a resuit of their structure, micelles can considerably enhance the
solubility of hydrophobic molecules in water and possibly protect the sequestered
dmg from chemical and/or enzymatic degradation in the host.
Micelles can be classified as either Iow-molecular weight surfactant micelles
or polymeric micelles depending on the molecular weight of the amphiphile. Low
molecular weight surfactant micelles typically have high CMC values and Iow core
viscosity, resulting in poor stability upon dilution in solution and in the blood stream
after intravenous (i.v.) administration [1$]. In addition, many low-molecular weight
surfactants cause adverse side reactions. for instance, Cremophor® EL has been
associated with severe hypersensitivity reactions in many patients [19J. These side
effects were also observed with polysorbate 80, but to a much lesser extent [20].
Compared to surfactant micelles, polymeric micelles have several advantages,
such as reduced toxicity, higher drug loading capacity and greater stability upon
dilution due to the lower CMC values, for example, poly(N-vinylpyrrolidone)-b
poly(D,L-lactide) (PVP-b-PDLLA) with 27 and 37% DLLA have CMCs of 10 and 6
mg/L, respectively [21]. These values are considerably lower than those of common
8fow molecular weight surfactants such as Cremophor® EL and polysorbate $0 with
CMCs of 90 and 100 mg/L, respectively [22].
PEG is commonly used as the hydrophilic segment of the block copolymer to
prolong systemic circulation time and target sites other than the celis ofthe MP$ [23].
Attaching targeting ligands to the hydrophilic block of polymeric micelles can
potentially improve drug delivery, although research on these systems is flot well
advanced yet [18]. Presently, a novel injectable polymeric micelle formulation of
paclitaxel (Genexol®, PEG-b-PDLLA) is being evaluated in Phase II clinical trials in
patients with advanced breast and non-small celi lung cancers [24]. This formulation
was reported to have lower toxicity and enhanced efficacy in mice compared to the
commercial low-molecular weight micelle formulation ofpaclitaxel (Taxol®) [25].
Micelles can also improve the delivery of genetic material by electrostatic
complexation of polyanionic DNA with a cationic segment of a block copolymer,
linked to a non-ionic, hydrophilic block. Neutralization of the oppositely-charged
polyions produces a water-insoluble segment, which forms the core of the micelle in
aqueous solvents [26]. The hydrophilic corona solubilizes the complex in aqueous
media and enhances stability in biological fluids. $uch systems are referred to as
polyion complex micelles.
The main drawbacks of micelles as drug delivery systems include rapid drug
leakage from the micelle and dissociation if diluted below the CMC. As a resuit, the
kinetics of micelle dissociation and drug diffusion are important parameters to
control.
94. Macromolecular prodrugs
Macromolecular prodrugs (also referred to as drug-polymer conjugates) are
delivery systems in which therapeutic agents are covalently linked to a polymer. The
polymer can be either naturally-occurring (e.g. starch amylase, pullulans, chitosan) or
synthetic (e.g. PEG, poly-amino acids, hydroxypropylmethacrylamide (HPMA),
polyvinylalcohol (PVA), polyvinylpyrrolidone (PVP)) [27]. These drug-polymer
conjugates are water soluble and generally have high molecular weights (> 40 kDa) to
overcome renal excretion and achieve extended plasma haif-lives. These polymeric
drugs can attain half-lives in the order of hours as opposed to a few minutes for drugs
in the free form [28]. Due to their relatively large size, drug-polymer conjugates
cannot diffuse through the celi membrane and thus are usually taken up by
endocytosis.
for this system to be efficacious the drug must be released from the polymer
at the target site, however, there are exceptions whereby the prodrug is active without
cleavage. In general, release of the drug from the polymer can be either pH-triggered
or enzymatic [27]. Prodrugs with pH-sensitive bonds can be cleaved in acidic
conditions such as the extracellular space of solid tumors and/or the endosomal or
lysosomal compartments after internalization by the celi [27]. In the case of enzyme
dependent release, the linker attaching the drug to the polymer is usually a peptide
spacer such as Gly-Phe-Leu-Gly, which is susceptible to cleavage by intracellular
enzymes [29]. Ideally, the macromolecular prodrug should remain stable in the blood
circulation until it reaches the target site. Similar to other colloidal drug carriers,
targeting moieties can be attached to macromolecular prodrugs to improve selectivity
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for the target site [30]. Examples of macromolecular prodrugs presently on the market
include PEG-interferon alpha, conjugate of neocarzinostatin and poly(styrene
comaleic acid) (SMANCS), and PEG-L-asparaginase [27].
Macromolecular prodrugs have two major disadvantages. first, for drugs that
are inactive as a conjugate, cleavage from the macromolecule must occur sufficiently
fast at the target site in order to achieve greater efficacy than the free drug. Second,
non-biodegradable polymers larger than 40 kDa cannot be eliminated by renal
filtration and thus will remain in the patient.
5. Polymeric nanoparticles
Polymeric nanoparticles consist of a dense polymer matrix, which can
physically entrap hydrophobic compounds. These particulates range in diameter from
10 — 1,000 nm and can be prepared from either natural or synthetic polymers [2$].
Nanopartic1es are interesting dmg delivery systems due to the dense polymer core,
which can considerably sustain or control the release of physically entrapped
molecules [31]. The release rate of the drug molecules from the nanoparticle is
controlled by the diffusion of the drug through the polymer matrix and the erosion of
the nanoparticle [32]. As a resuit of the polymeric matrix, nanoparticles are usually
more stable than liposomes and micelles in the presence of biological fluids. In
general, without proper surface modification nanoparticles are quickly removed from
the systemic circulation by the MP$. Incorporating PEG at the surface greatly
enhances the residence time of the nanoparticles in the blood stream.
The preparation of nanoparticles ofien requires organic solvents, which
presents a disadvantage for the use of this type of carrier in the clinic. Another
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potential problem is the biodegradability and toxicity of the degradation products.
Consequently, the polymer must be carefully selected.
6. Emulsions
Emulsions are heterogeneous mixtures of two immiscible liquids (i.e. ou and
water), whereby the one phase is dispersed as fine droplets in the other. The addition
of an emulsifier or surfactant provides kinetic stability to the preparation by reducing
the interfacial tension and increasing droplet-droplet repulsion through electrostatic
and/or steric repulsive forces [33]. Similar to other drug delivery vectors, emulsions
can protect the encapsulated drug against hydrolysis and enzymatic degradation in the
blood compartment, lower the toxicity of cytotoxic compounds, and can also provide
a certain level of selectivity towards target tissues, increasing the therapeutic index of
many drugs [34]. The application of emulsions as intravenous drug delivery systems
wiII be discussed in more detail in Chapter 2.
The goal of the present work was to develop long-circulating emulsions and
characterize their accumulation into solid tumors. The performance of the emulsions
was assessed in vivo in mice bearing either B16 melanoma or C26 colon
adenocarcinoma. The experimental section and resuits of this study are provided in
Chapter 3 in the form of a scientific article. A summary of these findings as well as
additional data on formulation optimization and stability are presented and discussed
in Chapter 4. Finally, the concluding remarks and perspectives are given in Chapter 5.
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1. Introduction
Emulsions can be defined as heterogeneous mixtures of two immiscible
liquids, in which one phase is dispersed as fine droplets in the other. Small ou
droplets dispersed in a continuous water phase is termed an ‘oil-in-water’ (olw)
emulsion. The opposite ofthis system is a ‘water-in-oil’ (w/o) emulsion, whereby the
water phase is dispersed in an oily extemal medium. Among these types, only 01w
emulsions can be used for intravenous administration [1]. Emulsions are
thermodynamically unstable systems that will eventually destabilize into two separate
phases. A third component, the surfactant or emulsifier, is added to stabilize the
preparation by reducing the interfacial tension and increasing droplet-droplet
repulsion through electrostatic andlor steric repulsive forces [2]. The addition of an
emu1siing agent however, only provides kinetic stability. Even though emulsions
are unstable systems, surface active agents may provide stability for several years,
making the system useful for practical application [2].
Lipid emulsions have traditionally been used for parenteral nutrition to deliver
essential fatty acids to patients unable to acquire them in food. Due to the successfiil
induction of Iipid emulsions in parenteral nutrition, there has been increasing interest
in developing emulsions as carriers for lipophilic drugs. Many intravenous lipid
emulsion formulations are commercially available (Table 1) and a number of others
are in clinical phase or in preclinical development (Table 2). Lipid emulsions are
promising carriers for drug delivery due to their biocompatibility, reasonable stability,
ability to solubilize high quantities of hydrophobie compounds and relative ease of
manufacture at an industrial seale [3, 4]. In addition, emulsions can protect the
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encapsulated drug against hydrolysis and enzymatic degradation in the blood
compartment, reduce drug loss in infusion sets, lower the toxicity of cytotoxic
compounds, and reduce the incidence of irritation and pain upon injection [1, 4]. They
can also provide a certain level of selectivity towards target tissues, increasing the
therapeutic index of many drugs [5]. However, afier intravenous injection, lipid
emulsions can acquire apolipoproteins and be metabolized as natural fats or be
recognized as foreign bodies and taken up by the ceils of the mononuclear phagocyte
system (MPS; also known as the reticuloendothelial system (RES)) [6]. Evading the
MPS or natural fat metabolism is necessary when the encapsulated drug is to be
delivered to non-MPS organs or liver parenchymal ceils, respectively. 11e in vivo fate
of lipid emulsions can be controlled to a certain extent by altering the
physicochemical properties of the carrier such as, droplet size, composition and
surface properties. This chapter will discuss the main factors to consider when
developing emulsions for intravenous injection.
2. Emulsion stability
Emulsions are thermodynamically unstable systems and will inevitably break
apart into separate ou and water phases. Emulsion instability is caused by the increase
in surface free energy tAG) as small droplets are formed as a resuit of the enhanced
surface area (AA). Adding a surfactant to the mixture reduces the interfacial tension
(y0) at the oil-water interface facilitating globule rupture during emulsification and
stabilizes the preparation (Eqn 1).
(1)
1$
It is important to state that surfactants only provide the emulsions with kinetic
stability, which delays the destabilization process. Nevertheless, surface active agents
can provide stability for several years, which is long enough for the system to be
useful for practical purposes [2]. Emulsions that are thermodynamically stable are
known as microemulsions. They are clear or transiucent systems and do flot require
much energy input during emulsification. In contrast, emulsions are cloudy and
require a greater amount of energy for emulsification [7]. The theory behind the
formation of microemulsions is beyond the scope of this chapter.
2.1. Destabijization processes
Emulsion destabilization can be characterized by three separate processes:
flocculation, coalescence and Ostwald ripening. Coalescence and Ostwald ripening
are irreversible processes which Iead to an increase in droplet size, requiring a large
energy input to re-disperse the droplets. flocculation, on the other hand, is reversible
and occurs when droplets aggregate to form a clump of many individual droplets. The
aggregated droplets move together as a cluster but each droplet stiil retains its
separate identity. The interactions holding the droplets together are weak and can be
broken by mild agitation. Even though floccules can be easily re-dispersed, they may
eventually fuse together to form single, larger globules. The fusion of droplets is
irreversible and is termed coalescence. Ostwald ripening, which also increases droplet
size, occurs in polydisperse formulations wherein the smaller droplets are more
soluble in the continuous phase than the larger ones. In this process, the oil from the
smaller droplets dissolves in the aqueous phase and diffuses towards the larger
droplets. This transfer of ou causes the big droplets to grow, while the smaller ones
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decrease in size. As the small droplets continue to shrink, the Ostwald ripening effect
is enhanced. The progressive increase in droplet size over time will eventually lead to
complete phase separation. Adding too much surfactant may promote Ostwald
ripening as the excess surfactant will form micelles which enhance the solubility of
the ou in the aqueous phase. Ostwald ripening can be reduced by increasing the
viscosity of the continuous phase, decreasing polydispersity, or adding a third
component which has a lower solubility in the continuous phase than the oil [8, 9].
Depending on the density differences between the dispersed and continuous
phases, individual droplets or floccules can cream or sediment. If the dispersed phase
is lower in density than the continuous phase, the droplets or floccules will rise to the
surface producing a highly concentrated layer of dispersed phase, which is known as
a cream. In the case where the dispersed phase is higher in density than the
continuous phase, a sediment will form at the bottom of the formulation. for o/w
emulsions, creaming usually occurs since the oil phase is typically less dense than the
aqueous phase. The rate of creaming or sedimentation can be linked to the size of the
droplet by Stokes’ equation (Eqn 2). According to this equation the limiting velocity
ofa falling sphere (u) is:
(2)
9v
where a is the radius of the droplet, Ap is the density difference between the dispersed
and continuous phases, y js the viscosity of the continuous phase and g is the
acceleration due to gravity. Stokes’ equation implies that droplets will rise or settie
faster if the droplet size or the density difference between the dispersed and
continuous phases is large, while an increase in continuous phase viscosity will slow
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down the separation process. As a resuit, creaming or sedimentation can be delayed
by reducing dropiet size, decreasing the density differences between the two phases
and increasing the viscosity of the continuous phase. Not much emphasis, however, is
being placed on density adjustments to produce stable emulsions since there are a
limited number of oils approved for intravenous administration and these oils have
similar densities.
$ubmicron emuisions have coiloidal properties and as a resuit are less
susceptible than coarse emuisions to the gravitational forces in Stokes’ equation [10].
Nanosized droplets are subjected to random Brownian motion and consequentiy are
less inclined to cream or sediment. Brownian motion, however, does flot provide
complete protection against instability since droplets may aggregate or coalesce upon
random collisions. Stability against these collisions depends on the attractive and
repulsive forces acting on the droplets. Typicaily, emulsions are stabiiized by either
electrostatic or steric repulsive forces (or a combination ofthe two).
2.2. Electrostatic stabilization
The balance between attractive Van der Waais forces and electrostatic
repuisive forces is described in the theory of coiloidal stabiiity, termed DLVO afier
its developers Derjaguin, Landau, Vervey, and Overbeek. If the net force is attractive,
the droplets wiil either flocculate or coalesce. In contrast, if the net force is repulsive,
the particles wiil repel each other and the system is stable. The attractive interaction
between particles arises from Van der Waals forces and is experienced by ail
particies. Van der Waals forces dominate at short separation distances and the
strength of this attractive force can be determined from the magnitude of the Hamaker
21
constant (A). Emulsions can overcome the attractive Van der Waals forces through
electrostatic repulsion with charged emulsifying agents. Electrostatic repulsion is
provided by the electric double-layer surrounding the droplet. The electric double-
layer is characterized by an adsorbed layer of fixed counterions and a diffuse layer of
ions that move freely with the fluid. Two approaching particles will experience a
repulsive force as the electric double-layers overlap. The total potential of interaction
between two droplets is the sum of the attractive van der Waals forces and the
electrostatic repulsive forces (Eqn 3);
V=V+J’Ç, (3)
where VT is the total interaction potential, VA represents the attractive van der Waals
forces and VR signifies the electrostatic repulsive forces. The potential energy of
interaction between two droplets as a function of separation distance is illustrated in
Figure 2. The repulsive barrier generated by the electric double-layer corresponds to
the maximum in the curve. The height of the energy barrier determines the stability of
the emulsion and depends on the ionization of the surfactants.
for the system to be stable, the energy barrier must be high enough sucli that
the droplets do flot have enough kinetic energy to surpass it and reach the primary
minimum. At the primary minimum (maximum attractive potential) droplet
coalescence readily occurs. flocculation takes place at the secondary minimum and
contrary to coalescence, is reversible by providing a small amount of kinetic energy
to overcome the weak attractive forces holding the droplets together. flocculated
droplets are prevented from coatescing as a resuit of this repulsive energy barrier. If
the flocculated droplets have enough energy to surpass the energy barrier they will
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easily reach the primary minimum and coalesce. The strength of the electrostatic
forces can be quantified by measuring the zeta potential, which is the potential at the
plane of hydrodynamic shear. Generally, emulsions are stabilized by electrostatic
repulsive forces if the zeta potential is greater than ± 30 mV [2, 8, 1 1]. An emulsion
stabilized by electric double-layer repulsion can be destabilized if the concentration
of electrolytes is increased above a critical value. Adding electrolytes to an emulsion
decreases the electric double-layer repulsion potential, while the van der Waals
attractive potential remains unchanged. As electrolyte concentration increases, the
repulsive forces stabilizing the colloid become weaker until the net force is attractive
and stability is lost.
2.3. Steric stabilization
Emulsions can also be stabilized by steric repulsion by grafiing long-chain
polymers at the emulsion interface. Steric repulsion is a non-DLVO interaction that
occurs due to the unfavorable overlap of the polymer chains as two particles approach
each other [8, 12]. Steric stabilization occurs at short inter-droplet separation
distances and can provide a strong barrier against coalescence [8]. Optimal steric
repulsion can be achieved at high polymer surface density as desorption and chain
rearrangement is minimized [8].
3. Elimination mechanisms for lïpid emulsions
Afier intravenous injection, lipid emulsions may be metabolized in a manner
similar to chylomicrons or might be recognized as foreign bodies and removed by the
ceils of the MPS. The mechanism of elimination from the body depends on the
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physicochemical properties of the emulsion. Both mechanisms of elimination can
occur for a given lipid emulsion, however, one process may be favored over another.
This section describes the two primary pathways of lipid emulsion elimination from
the body.
3.1. Lipid emulsions metabolized as endogenous chylomicrons
Depending on the composition and surface properties, lipid emulsions may be
recognized as chylomicrons and be elirninated via the fat metabolism pathway.
Chylomicrons are endogenous emulsions produced by the enterocytes of the small
intestine afier dietary lipids are ingested. They are rich in triglycerides and possess
apolipoproteins A-I, A-IV and 3-48 prior to entering the blood circulation (Figure 3)
[13]. Chylomicrons are secreted into the lymph and enter the systemic circulation
through the thoracic duct. After entering the blood, chylomicrons obtain Apo C-II and
Apo E from the high-density lipoproteins (HDLs) and release Apo A-IV. In the
capillaries of adipose tissues and muscle, lipoprotein lipase (LPL) located on
endothelial ceils adsorb onto the mature chylomicron and hydrolyze the triglycerides
to fatty acids [14]. The fatty acids are then absorbed mainly by adipose tissues and
muscle. During lipolysis, a substantial amount of phospholipid, Apo A and Apo C are
transferred to the HDLs and the size of the chylomicron is reduced considerably. The
remuant chylomicrons composed of mainly Apo B-48, Apo E and cholesterol are
quickly removed from the blood by the liver. The uptake of remuant chylomicrons by
the liver occurs via two Apo E-specific recognition sites on parenchymal ceils, which
are the low-density lipoprotein receptor (LDLr) and the remuant receptor [15-17].
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Injectable lipid emulsions differ from chylomicrons in that they do flot have
apolipoproteins on the surface prior to entering the blood stream, although they may
acquire them afier systemic injection. Emulsions rich in triglycerides are known to
acquire apolipoproteins (Apo C-I, C-II, C-III, E and possibly Apo A-IV), mainly from
HDLs, soon afier injection into the systemic circulation and are metabolized in a
pathway comparable to that described for chylomicrons [15, 18, 19]. Among the
apolipoproteins acquired Apo C-II and Apo E are essential for LPL activation and
uptake of remnant emulsions by the liver, respectively [19].
Elimination of the lipid emulsion via the pathway of natural fat metabolism
may be desirable when the liver parenchymal ceÏÏs are the target site. On the other
hand, if the target site is flot the liver then apolipoprotein adsorption onto the
emulsion should be avoided. The metabolism of lipid emulsions as natural fats is
strongly dependent on the type of emulsifier [20, 21], the presence of cholesterol [22]
and the chain length ofthe triglyceride ou [23].
3.2. Elimination by the mononuclear phagocyte system
If the body recognizes the lipid emulsions as foreign, they will be captured by
the ceils ofthe MPS, mainly the Kupffer celis ofthe liver and the macrophages ofthe
spleen, and removed from the systemic circulation. The MPS takes up the emulsions
via endocytosis and localizes them in the lysosomal compartment where they are
degraded by enzymes [24]. The extent of emulsion clearance from the systemic
circulation is enhanced by the adsorption cf opsonins (proteins) onto the colloid
surface. The bound proteins then interact with the receptors on monocytes and
macrophages, facilitating endocytosis. Carriers that become bound te opsonins will be
25
rapidly cleared from the blood and prevented from reaching the target site(s) [24].
Immunoglobins and complement components such as Clq and C3 fragments (C3b,
iC3b) are well known opsonins.
A major challenge in drug delivery using colloidal nano-carriers is to avoid
clearance by the celis of the MPS when the target sites are non-MPS tissues.
Overloading or saturating the MPS with large injections volumes has been shown to
enhance the circulation time of lipid emulsions [25]. However, temporary impairment
of the MP$ may pose a health hazard to the patient [26J. Altematively, the clearance
rate of carriers from the blood can be altered by modifying the physicochemical
properties of the emulsion, such as droplet size [27, 28] and surface characteristics
[29]. This will be discussed in detail in section 4.
4. Biodistribution of lipid emulsions
The biodistribution of an emulsion after systemic injection is dependent
primarily on the droplet size, composition and surface properties. A certain specificity
towards the target site can be achieved by controlling the physicochemical properties
of the emulsion. The principle factors that influence the biodistribution of emulsions
has already been very thoroughly reviewed in a book chapter by Nishikawa [6]. This
section provides a brief overview of these factors and has been updated with some
recent work.
4.1. Effect of lipid emulsion size
It is well known that droplet size greatly influences the uptake of the
emulsions by the MP$ [27, 28]. In general, larger particles are more susceptible to
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uptake by the MPS and are cleared more quickly from the systemic circulation. The
influence of droplet size on the in vivo biodistribution of lipid emulsions was
explored by Takino et al. [27]. The authors compared the biodistribution of large (250
nm) and small (100 nm) lipid emulsions composed of egg phosphatidylchoÏine (egg
PC):soybean ou = 1:1. [‘4C]Cholesteryl oleate ([14C]CO), a highly lipophilic
compound (log P = 18.3) that does flot undergo lipolysis by LPL and remains
associated with the emulsion, was incorporated into each emulsion to track the
ehmination of the whole droplet [30]. The large egg PC emulsion was rapidly
eliminated from the blood with 60% of the injected emulsion recovered in the liver
within 10 min. The small egg PC emulsion, however, remained in the blood for
longer and accumulated less in the liver. Similarly, Lundberg et al. [28] reported that
droplet size influenced emulsion clearance rate from plasma. They observed that the
smallest emulsion (50 nm) survived the longest in plasma, whereas the larger
emulsions (100 and 175 nm) were cleared more rapidly (figure 4). The influence of
emulsion-like lipid nanocapsule size (20, 50 and 100 nm) on the extent of
complement activation and macrophage uptake was evaluated by Vonarbourg et al.
[31]. Similar to emulsions, Iipid nanocapsules are core-sheil structures with an oily
internal phase that is stabilized by a monolayer of emulsifiers. They differ from lipid
emulsions in the physicochemical properties of the hydrophilic/hydrophobic
interface. In lipid nanocapsules, the emulsifiers form a semi-rigid sheil, while the
interface is more fluid in emulsions. The authors observed that larger lipid
nanocapsules were stronger activators of the complement and were taken up more by
macrophages than the smaller ones.
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The size of the lipid emulsion was also shown to influence lipolysis. Kurihara
et al. [32] found that the rate of lipolysis was much faster for the small sized
emulsions (‘- 100 nm) in vitro compared to the larger ones (225-416 nm). However,
afier intravenous injection of these formulations in rats, they observed that the small
sized emulsions remained in plasma longer than the larger ones, which is consistent
with the studies of Takino [27] and Lundberg [2$]. Consequently, even though small
emulsions were better substrates for LPL, large emulsions were cleared from the
blood faster, which suggests a greater uptake by the MPS.
Droplet size also determines the ability of the emulsion to escape the systemic
circulation through the blood capillaries and reach the extravascular space. Capillary
walls are composed of a single layer of endothelial celis surrounded by a basement
membrane. They are classified into three types, continuous (intact), fenestrated or
discontinuous (sinusoidal), based on their wall structure [33]. Both fenestrated and
discontinuous capillaries have pores in the endothelium, while continuous ones have
tightjunctions between adjacent endothelial ceils [34]. Continuous capillaries have an
intact subendothelial basement membrane and can be found in most regions of the
body such as the skin, connective tissue, skeletal and cardiac muscle, alveolar
capillaries of the lung, and the brain [33]. In fenestrated capillaries, the pores
(fenestrae) are approximately 40-80 nm in diameter and they can be either open
(unobstructed) or covered by a thin diaphragm [33]. These capillaries have a
continuous subendothelial basement membrane and are situated in the intestinal
mucusa, pancreas, glomerulus, peritubular capillaries, endocrine glands, the choroid
plexus ofthe brain and the ciliary body ofthe eye [33]. Discontinuous capillaries, on
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the other hand, have large gaps between endothelial ceils and are located in the liver,
spleen and bone marrow [33]. The basal membrane is either absent, which is the case
for the liver or discontinuous (spleen and bone marrow) [34J. The largest pore size in
the capillary endothelium is believed to be approximately 100 nm [35]. Nanoscopic
drug carriers are generally too large to diffuse across the capillaries of continuous
endothelium. Their best opportunity to escape the systemic circulation is through the
gaps between the endothelial ceils of discontinuous capillaries. Consequently,
colloidal drug carriers tend to accumulate in the liver, spleen and bone marrow.
Control over carrier size can impart some selectivity for the extravascular
space of tumoral sites, reducing anticancer drug toxicity towards healthy tissues. This
selectivity can be achieved by taking advantage ofthe difference in capiflary structure
between tumors and normal tissues. Tumor vasculature is often characterized as
porous or “leaky” allowing enhanced permeation of colloidal particles across the
endothelium and into the extravascular space. In addition, tumors have poor
lymphatic drainage allowing colloids to be retained in the tissue for longer periods of
time [36]. This increased permeation and retention of colloids is called the enhanced
permeation and retention (EPR) effect [37]. The optimum size range for colloidal
particle accumulation in tumors is generally accepted to be approximately 5 0-200 nm
[38]. Particles in this size range can be convected from the blood vessel into the
extravascular space through the porous vasculature of the tumor. Depending on the
porosity of the tumor capillaries, particles above 200 nm may not pass through the
pores and will be eliminated more quickly by the MPS. On the other hand, particles
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less than 50 nm will easily extravasate through the discontinuous endothelium of the
liver, spleen and bone marrow.
As a rule of thumb, for successffil accumulation of dmg in the tumor by the
EPR effect, the concentration of colloidal carriers in the plasma must remain high for
more than 6 hours [39]. The progressive extravasation of the carrier into the tumor
tissue over several hours wiii resuit in increasing concentrations of anticancer drug in
the vicinity of the cancer ceils. Kurihara et al. [40] demonstrated that lipid emulsions
under 230 nm in diameter could deliver more RS-1541, a highly lipophilic antitumor
agent (13-0-palmitoyl-rhizoxin), to the tumor site (M5076 sarcoma ceils) than larger
dropiets (Figure 5). The low concentrations of RS-1541 detected in the tumor for the
larger emuisions is most likeiy due to the impermeability of the leaky tumor
capiilaries to large particles and their faster removal rates from blood. It was also
observed that emulsions greater than 220 nm reduced the toxicity of R$-1541 as
shown by the higher maximum tolerated dose (MTD) with increasing size (Table 3).
Ail emulsions regardless of size (70 — 380 nm) suppressed tumor growth and
improved survival at the MTD. The medium sized emulsions (220 nm), however,
displayed the highest antitumor activity at the MTD due to the permeability of the
tumor vasculature for the emulsions and reduced toxicity, permifting the injection of a
higher dose. Hence, lipid emulsions can augment the delivery of cytotoxic
compounds to tumoral sites and reduce systemic toxicity by suitable selection of the
droplet size.
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4.2. Effect of lipid emulsion composition and emulsifiers
Composition ofthe oitphase
The composition of the internai phase has aiso been shown to alter the
biodistribution of lipid emulsions. Lutz et al. [41] observed that lipid emuisions
composed of medium-chain triglycerides (MCTs) were cleared from plasma more
quickly than those prepared with long-chain triglycerides (LCT5). This is probably
due to the faster hydrolysis of MCTs by LPL and hepatic lipases compared to LCTs
as a resuit of the greater solubility and mobility of shorter chain triglycerides at the
oil/water emulsion interface [42].
Adding free cholesterol bas also been shown to alter the metabolism of
triglyceride emuisions. Maranhao et al. [22] observed that emulsions with low free
cholesterol content (< 4, % w/w) were metabolized in a maimer similar to
chylomicrons, as shown by the faster removal rate of triglycerides from the blood
than CO due to LPL mediated hydrolysis of the ou and greater uptake of CO than
triglycerides by the liver. In contrast, emulsions with high free cholesterol (>16, %
w/w) displayed similar triglyceride and CO removal rates from blood and equal
uptake by the liver. The group also observed that emulsions containing high ftee
cholesterol bound less Apo A-I, Apo A-IV and Apo C and more Apo E in vitro. Apo
C-II us essential for LPL binding and activation and hinders liver uptake, while Apo E
facilitates emulsion uptake by the liver. Hence, the presence of free cholesterol may
modify the metabolism of the droplets by altering the binding of apolipoproteins onto
the surface.
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Pizosphatidytchotine composition
The biodistribution of emulsions can also be altered by the pliospholipid
emulsifier. Lenzo et al. [43] demonstrated that the nature of the PC affected the
metabolism of the emulsion in rats. Five lipid emulsions with different phospholipid
emulsifiers were prepared. The phospholipids selected were egg PC, 1,2-dioleoyl-sn-
glycero-3 -phosphatidylcholine (DOPC), 1 ,2-dimyristoyl-sn-glycero-3
-
phosphatidylcholine (DMPC), 1 ,2-dipalmitoyl-sn-glycero-3 -phosphatidylcholine
(DPPC) and 1 -palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC). The
average composition of each emulsion was similar and size was maintained at
approximately 150 nm. The emulsions were radiolabeled with [‘4C]triolein (TO) and
[3H]CO or dipalmitoylphosphatidyl{N-methyl-3HJcholine to monitor the hydrolysis of
the triglyceride ou by LPL, the clearance of the entire colloid particle and the transfer
ofphospholipids to the HDLs, respectively.
The carriers emulsified with egg PC or POPC were metabolized in a manner
similar to chylomicrons as shown by the rapid removal rate of [‘4C]TO from plasma,
consistent with hydrolysis by LPL and the efficient uptake of [3H]CO (remuant
emulsions) by the liver. DPPC-based emulsions remained in plasma the longest and
the triglycerides associated with this emulsion disappeared very slowly, suggesting
that the emulsion was less susceptible to hydrolysis by LPL. Moreover, the
phospholipid radiolabel did flot transfer to HDLs. A possible explanation for the
above observations is the difference in chain unsaturation between the five
phospholipid emulsifiers. The authors hypothesized that rapid hydrolysis of the
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triglyceride ou by LPL and efficient transfer of phospholipids to HDLs requires a
chain unsaturation at the glycerol 2-position.
4.3. Effect of surface charge
Lipid emulsions obtain their surface charge through the use of neutral, anionic or
cationic emulsifiers. Most emulsions used in drug delivery are either neutral or
negatively charged since cationic carriers are more prone to aggregate in the presence
of plasma proteins. This susceptibility for aggregation in the bloodstream is a resuit of
the electrostatic interactions with negatively charged plasma proteins. It is generally
accepted that surface charge has an effect on the rate of particle uptake by the MPS,
although the connection is far from straightforward. Other surface properties, such as
the nature of the emulsifier may take precedence over the effects generated by surface
charge. Davis et al. [44] found no clear correlation between zeta potential and the rate
of emulsion uptake by mouse peritoneal macrophages, although emulsions with the
weakest charge, prepared with the non-ionic surfactant poloxamer 338, had the
slowest rate of uptake. Stossel et al. [45] found that emulsions with higher surface
charge (positive or negative) were phagocytosed at a faster rate compared to neutral
or weakly charged surfaces. Oku et al. [46] observed that uptake by the liver and
spleen was greater for positively charged liposomes than neutral or anionic ones. The
higher accumulation of cationic liposomes in the MPS organs may be due to both
particle aggregation in the presence of serum and protein adsorption onto the colloid,
which was observed to a lesser extent in neutral or anionic liposomes. Devine et al.
[47] found that liposomes bearing a net positive or negative charge activated the
complement in a dose-dependent manner, while no complement activation was
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obseiwed for neutral liposomes. Interestingly, long-circulating cationic lipid
emulsions have been reported in the literature by careful selection of the emulsifier
[48].
Over the past several years, there has been increasing interest in developing
cationic lipid-DNA complexes for the improved delivery of genetic material [49, 50].
An advantage of using cationic carriers is the enhanced cellular uptake via
endocytosis over neutral or negatively charged carriers [51]. This is due to the
favorable electrostatic interactions of cationic particles with the negatively charged
moieties on biological membranes. However, due to the tendency of cationic particles
to aggregate in the presence of serum, the positive charge will need to be shielded,
which will invariably reduce transfection efficiency in the absence of targeting
ligands.
4.4. Long-circulating lipid emulsions
Afier intravenous administration, colloidal drug carriers are rapidly taken up
by circulating monocytes and macrophages in the liver, spleen and bone marrow.
Avoiding the MPS is crucial when the emulsions are to be delivered to non-MP$
ceils. ProÏonged circulation of the drug carrier is also necessary to achieve passive
targeting of tumoral tissues via the EPR effect. Modifying the colloidal surface such
that the carriers are invisible or “stealth” to opsonins and macrophages is an approach
investigated to increase the circulation time of submicrometer emulsions in blood.
$phingomyetin
The presence of sphingomyelin (SM) at the oil/water interface lias been
shown to reduce the uptake of the emulsions by the MPS. Takino et al. [27]
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demonstrated that adding SM to an egg PC and soybean ou formulation increased the
circulation time of the submicrometer ernulsions in blood and decreased liver and
spleen uptake. The emulsions were composed of egg PC:soybean ou = 1:1 and egg
PC:$M:soybean ou = 0.7:0.3:1 with [14C]CO incorporated as a radiolabeled tracer.
The AUC of the SM emulsion was 1.6 times larger than the one emulsified with egg
PC only. Similarly, Redgrave et al. [21] observed that increasing the amount of SM
enhanced the circulation time of the carrier in plasma (figure 6) and reduced uptake
by the liver (figure 7). Even though SM and PC share a common phosphorylcholine
polar head group, there are structural discrepancies between the two molecules that
reflect their different physical properties in colloidal systems. SM has a high content
of saturated acyl chains relative to naturally occurring PCs and has a stronger
hydrogen bonding capacity, which may alter monolayer rigidity and interactions with
blood components [52].
Poty(ethytene glycol)-tipids
A very widely used and effective method to avoid clearance by the MPS is to
incorporate poly(ethylene glycol) (PEG) (also known as poly(ethylene oxide) (PEO))
at the colloid surface using a lipid derivative. PEG, a hydrophilic and flexible
polymer, creates a zone of steric hindrance around the carrier which decreases the rate
and extent of opsonin binding [53]. PEG is widely accepted for intravenous
administration because it is a biocompatible, non-toxic and non-immunogenic
polymer. Moreover, PEG-lipid derivatives are amphiphilic and as a result can be used
as a coemulsifier as well. Liu et al. [29] observed the influence of PEG molecular
weight on the biodistribution of lipid emulsions composed of castor oil and egg PC.
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The PEG-lipid derivatives investigated were dioleoyl N-(monomethoxy PEG
succinyl)phosphatidylethanolamine (PEG-DOPE) (MW 1000, 2000, and 5000) and
poly(ethylene oxide) 20 sorbitan monooleate (polysorbate $0). Emulsion droplet size
was maintained at approximately 200 nm so that the circulation behavior was only
dependent on the surface properties of the emulsions. It was observed that emulsion
circulation time in blood depended on the length of the PEG chain. PEG2000-DOPE
and PEG5000-DOPE kept the emulsions in the blood the longest. Approximately 60-
70% of the injected dose remained in the blood after 30 min. PEG1000-DOPE and
polysorbate $0 emulsions demonstrated comparable behavior in vivo with 47% of the
injected dose remaining in the blood afier 30 minutes. The high emulsion
concentration observed in the blood for PEG2000-DOPE and PEG5000-DOPE translated
into lower accumulation in the liver. Consequently, coating an emulsion surface with
PEG of sufficient chain length can confer long circulating properties to
submicrometer emulsions.
Hoarau et al. [3$] evaluated two different processes to incorporate 1,2-
distearoyl-sn-glycero-3 -phosphatidylethanolamine-N-monomethoxy-[PEG] (PEG
D$PE) into lipid nanocapsules. The conventional method was the first investigated
and involved the addition of PEG-DSPE with the other surfactants during the
emulsification ofthe oil. The second method evaluated was post-insertion, wherein an
aqueous micelle solution of PEG-D$PE was added to the preformed lipid
nanocapsules and then incubated for 90 min at 60°C. The authors observed that the
post-insertion method enhanced the amount of PEG-DSPE that could be incorporated
into the nanocapsule compared to the conventional process. for the conventional
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method, the amount of PEG2000-DSPE and PEG5000-DSPE could flot exceed 3.4 and
1.5 mol% of the total surfactants, respectively as physical instability would occur. In
contrast, PEG-DSPE could be incorporated into the lipid nanocapsules at higher
quantities (6-10 mol%) using the post-insertion method, regardless of the PEG chain
length. Consequently, the PEGylated lipid nanocapsules prepared by the post
insertion technique circulated longer in blood due to the greater PEG density at the
surface (figure 8). for example, the AUC increased 5-fold as the proportion of
PEG2000-D$PE increased from 1.7 to 10 mol%.
Other methods to enhance circulation time
Surfactants containing PEO chains such as, PEO-b-poly(propylene oxide)-b
PEO (PEO-b-PPO-b-PEO, poloxamers) and PEO-hydrogenated castor ou
(cremophors) have also been investigated to enhance the hydrophilicity of emulsion
surfaces to reduce opsonin binding and uptake by the MPS. Lee et al. [54]
demonstrated that emulsions coated with poloxamer 338 reduced the amount of
ibuprofen octyl ester delivered to the MPS organs. Ueda et al. [55] investigated the
influence of ethylene oxide number in PEO-hydrogenated castor oil surfactants on
menatetrenone clearance rate from plasma and distribution to MPS organs. They
observed that a minimum of 20 ethylene oxide units (MW = $80) is required to
prolong menatetrenone circulation time in plasma. The prolonged circulation of
emulsions containing greater than 20 ethylene oxide units translated into a lower
accumulation of menatetrenone in the liver. Menatetrenone incorporated into
emulsions with 10 ethylene oxide units were rapidly removed from plasma and were
taken up to a greater extent by the liver.
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4.5. Active targeting of selected celis
Dmg delivery systems utilizing ligands that specifically recognize
determinants on the surface of target ceils has been extensively investigated in
liposomes [56-5$] and macromolecular prodrugs [59]. However, few studies have
been done with emulsions. Incorporating ligands onto the emulsion interface is a
promising method to enhance specificity towards the target site(s). for this method to
be successful, Iipid emulsions must have the appropriate ligand(s) anchored onto the
surface, be able to reach the target ceils, bind to the receptors and either enter the ceil
or empty the contents in the vicinity ofthe ceil.
Lipid emutsions associated with apottoprotein E
Apo E has an affinity for both the remnant and LDLr receptors on hepatocytes
and is an important mediator in the uptake of emulsions and lipoproteins by the liver.
Incorporating Apo E on lipid emulsions provides an opportunity to target hepatocytes.
Rensen et al. [60] investigated the possibility ofusing lipid emulsions associated with
Apo E as drug carriers for a mode! antiviral prodrug, iododeoxyuridine-oleoyl (IDU
012), to selectively target hepatocytes for improved therapy of hepatitis B viral
infection. The emulsions were prepared using natural Iipids (egg PC,
lysophosphatidytcholine, cholesterol, TO and CO) and had a mean size of
approximately $0 nm to mimic natural chylomicrons. The lipid emulsions were
radiolabeled with [‘4C]CO and [3H]IDU-017 to track the in vivo distribution of the
whole droplet and prodrug, respectively. Afier intravenous injection, lipid emulsions
pre-loaded with Apo E were removed faster from serum and were taken up more by
the liver than the control emulsions (lipid emulsions flot pre-loaded with Apo E)
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(Figure 9). The uptake of the carrier by the liver reached approximately 70% of the
injected dose for the Apo E pre-loaded emulsion compared to only 30% for the
control. The prodrug exhibited similar removal rates from serum and uptake by the
liver as the carrier. The authors also showed that the carrier and prodrug were mainly
taken up by parenchymal celis with littie accumulation in the endothelial or Kupffer
cells. Introducing lactoferrin, a glycoprotein that blocks Apo E mediated uptake of
lipoproteins by parenchymal cells, prior to injecting the lipid emulsions resulted in a
considerable reduction in emulsion uptake by the liver.
Sugar-coated emulsions to target hepatocytes
Incorporating Apo E onto the lipid emulsion is a complex process which may
cause reproducibility and stability issues [61]. Another method to enhance selectivity
for hepatocytes is to incorporate sugars such as galactose on the surface of the lipid
emulsion to target the carbohydrate receptors on hepatocytes. Ishida et al. [61]
investigated the biodistribution of galactosylated (Gal) and non-galactosylated
emulsions afier intravenous injection in mice. The results demonstrated that the Gal
emulsion was more quickly removed from the blood compared to the bare-emulsion,
whereby the AUC values for the Gal-emulsion and bare-emulsions were 1.9 and 3.7
(% of dose x bJmL), respectively. In addition, the uptake of the Gal-emulsion by the
liver was 3.2-times greater than the bare-emulsion. Moreover, Gal-emulsions were
taken up 7.4-times more by parenchymal cells than non-parenchymal compared to
only 4.3-times for the bare-emulsions. These findings suggest that introducing
galactose on the surface of lipid emulsions is a promising method for delivering drugs
to hepatocytes.
39
Antibody/peptide conjugation onto long circutating t,pid emutsions
Cancer celis ofien over-express certain antigens or receptors, which provides
another possible method to enhance the selectivity of anticancer drugs towards tumor
tissues [58]. Antibodies, antibody fragments, or synthetic peptides can be
incorporated onto the carrier surface to specifically recognize the antigenlreceptors on
cancer celis and offers a possible solution to the non-specific and slow uptake of
colloidal carriers by cancer ceils. Linking antibodies to liposomes has been widely
studied, however, much more progress is required for its successful application [58].
In theory, the techniques applied to liposomes can be carried over to lipid emulsions.
Ideally, the tumor targeting ability of antibodies can be coupled with the long
circulating properties of PEGylated lipids. To avoid the interference between the PEG
chain of PEGylated lipid emulsions and the antibodies incorporated into the emulsion
surface, antibodies linked to PEG chains have been developed in recent years.
Lundberg et al. [62] successfully conjugated an anti-B-cell lymphoma monoclonal
antibody (LL2) onto a lipid emulsion by coupling LL2 to PEG-D$PE. The
immunoreactivity of the LL2 conjugated emulsion was tested by determining their
binding affinity to WN, the anti-idiotype antibody to LL2. The results showed that
increasing the density of LL2 at the surface enhanced the binding of the emulsion to
WN up to 40 antibodies per droplet.
4.6. Drug leakage from emulsions
Drug retention within the droplet afier intravenous administration is another
important factor to consider when designing lipid emulsion flot only for dissolution
purposes but as carriers for lipophilic drugs. Controlling the biodistribution of the
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entire droplet will flot enhance the therapeutic effect if the drug is released from the
carrier before it reaches the target site. Takino et al. [27] suggested that the drug must
have adequate lipophilicity (log P greater than 9) to remain sufficiently incorporated
in the emulsion in the blood circulation. The influence of lipophilicity on drug
leakage was observed by Kurihara et al. [63]. The group evaluated the
pharmacokinetics of two lipophilic anticancer agents, rhizoxin and RS-1541,
incorporated into lipid emulsions afier intravenous injection in rats. The
lipophilicities of rhizoxin and RS- 1541 were very different with log P values of 1.9
and 13.8, respectively. Afler intravenous injection, rhizoxin was removed much more
quickly from plasma than RS-1541 and distributed more to the liver, lung and
intestine. The different pharmacokinetic profiles can be attributed to the lower
retention of rhizoxin within the lipid emulsion afier injection. Similarly, $akaeda et
al. [64, 65] found that sudan II with a log P of 5.4 was rapidly released from the lipid
emulsion in plasma. Consequently, the lipid emulsion did not alter the
pharmacokinetics of sudan II. The lipophilicity of a drug can be increased by
chemically modifying the drug. A drawback of this approach, however, is that
chemical modifications may reduce efficiency or completely inactivate the drug.
5. Preparation of emulsions for intravenous administration
To be used for intravenous administration, emulsions must be biocompatible,
biodegradable, non-toxic, sterile, isotonic, physically and cliemically stable, and non
immunogenic [1]. Moreover, droplet size must be small enough to avoid forming
pulmonary emboli. To achieve these requirements, the excipients, additives and
manufacturing conditions must be carefully selected. In addition, a complete
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physicochemicai characterization of the emuisions is necessary, foliowed by a long
term stabiiity testing schedule on ail promising formulation candidates. The following
section describes the basic factors that need to be considered when developing
emulsions for intravenous injection.
5.1. Excipient and formulation considerations
Internatphase (oits)
To compiy with the essential requirement of biocompatibility, research on
injectable emulsions lias been primarily focused on the use of vegetable oils
(triglycerides) as the ou phase [66]. Triglyceride oils can be characterized as long,
medium or short chain depending on the number of carbon atoms per hydrocarbon
chain. LCTs contain 14, 16, 18, 20 or 22 carbons in a fatty acid chain, which may or
may flot have unsaturations [24]. MCTs are derived from coconut ou and contain
saturated fatty acids with chains of 6, 8, 10 or 12 carbons [1, 24, 67]. Lastly, short
chain triglycerides (SCTs), such as triacetin and tributyrin have chain lengths of only
2 and 4 carbons, respectiveiy. LCTs and MCTs should be considered in the initiai
stages of formulation as many of these oils are approved for injection and are found
in a number of FDA (food and Drug Administration) approved products [67] (Table
4). The choice of ou is usually dependent on the solubility and stability of the drug.
MCTs have 100-fold greater water solubility than LCTs and consequently are
typically better solubilizers for dmgs since most hydrophobic drugs have some
polarity [24, 67]. Kan et al. [6$] reported that triglycerides with short fatty acid chains
were better solubilizers for paclitaxel, a lipophulic anticancer drug. They reported that
paclitaxel solubility increased as the number of carbons per hydrocarbon chain
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decreased. for example, tributyrin (C4) and tricaproin (C6) provided greater
paclitaxel solubility than tricaprylin (C$) and other plants oils with a mixture of 6-22
carbons per hydrocarbon chain. Triacetin (C2) gave the highest paclitaxel solubility at
a value of 75 mg/mL. Triacetin, however, is flot approved for injection and might be
difficult to emulsify due to its relatively high water solubility.
Vitamin E (DL-a-tocopherol) has been investigated as an alternative
biocompatible oil to triglycerides to solubilize highly lipophilic drngs [69-71].
Constantinides et al. [70-72] have formulated a submicrometer emulsion of paclitaxel
with high drng loading (8-10 mg/mL) using vitamin E as the internaI phase and d-a
tocopheryl polyethylene glycol 1000 succinate (TPGS) and poloxamer 407 as the
emulsifiers (TOCOSOL®-paclitaxel). This formulation is less toxic and has greater
antitumor activity in mice bearing Bi 6-melanoma tumors than the commercial
formulation for paclitaxel (Taxol®). At the MTD for Taxol® (20 mg/kg),
TOCO$OL®paclitaxel showed greater tumor regression than Taxol® on a q3dx5
dosing schedule. Moreover, tumor growth was suppressed further at higher doses of
this formulation (40 mg/kg and 60 mg/kg). TOCOSOL®-paclitaxel is currently in
Phase III clinical trials [72]. In addition to being a solubilizer for poorly soluble
drngs, vitamin E may also provide some therapeutic value. Bartels et al. [73]
examined the influence of vitamin E, administered intravenously in an emulsion
before surgery, on ischemia and reperfusion (TIR) injury in a double-blinded study on
68 patients. T/R injury is usually an outcome of liver surgery, which causes oxidative
stress and cdl damage. The results of the study indicated that administering vitamin E
prior to surgery may reduce the impact of I/R injury in liver surgery. The antioxidant
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activity of vitamin E has also been shown to protect against doxorubicin-induced
cardiotoxicity in animal studies [74, 75]. Moreover, vitamin E was found to enhance
the anticancer activity of doxorubicin on human prostatic carcinoma ceils in vitro
[76].
Another possible internai phase for intravenous emulsions is
perfluorocarbons. Emulsions containing perfluorochemicals have been investigated as
contrast agents for diagnostic tissue imaging or as carriers for the transport of oxygen
offering an alternative to blood transfusions [77, 78]. Perfluorochemicals are
chemically inert, synthetic molecules containing carbon and fluorine atoms, and are
capable of dissolving considerable amounts of oxygen [7$]. They are hydrophobic
and as a result require emulsification for dispersion in aqueous media. $everal types
of perfluorochemicals have been investigated such as, perfluorooctyl bromide
(C8f17Br), perfluorodecyl bromide (C10F21Br) and perfluorodichlorooctane
(C8f16C12). Imavist® (formally known as Imagent®) and Oxygent® are
perfluorocarbon emulsions presently undergoing clinical trials as an ultrasound
contrast agent and artificial blood substitute, respectively.
Emutsfiers
The purpose of surfactants is to emulsify the oil phase and to provide physical
stability against flocculation and coalescence during storage, which may be for
extended periods of time. Surfactants provide physical stability by reducing the oll
water interfacial tension and promoting droplet-droplet repulsion. Injectable
emulsions are frequently emulsified with natural lecithins obtained from either egg
yolk or soybeans. These lipids are biocompatible, biodegradable and have relatively
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good emulsifying properties [79]. Lecithins differentiate in the nature of the
headgroup and in the length and degree of saturation of the acyl chains. The
headgroup can be either phosphatidic acid (PA), ethanolamine (PE), serine (PS) or PC
and determines the surface charge of the emulsion. At pH 7, PE and PC headgroups
are uncharged, while PA and P5 are anionic. Surface charge can promote long-term
emulsion stability by electrostatic repulsion and can influence its biodistribution in
vivo.
The length and degree of saturation of the acyl chains greatly influences the
gel-liquid phase transition temperature (Te) and the surface properties of lipid bilayers
(liposomes) and monolayers (emulsions). The T refers to the temperature at which
the lipids shifi from a highly ordered gel state to a less ordered fluid. Saturated lipids
generally have phase transitions above room temperature (e.g. T of 1 ,2-distearoyl-sn-
glycero-3-phosphatidylcholine (DSPC; C18:O) is 58°C) [12, 79]. Introducing
unsaturations or reducing the Iength of the acyl chains decreases the T substantially
(e.g. T ofDOPC (C18:1) is -22°C and T ofDMPC (C14:O) is 23°C) [12, 79]. Most
natural phosphatides have chain Iengths of 16 to 18 carbons, however, chains with as
little as 4 carbons also exist. Nu et al. [79] observed that both PC acyl chain length
and degree of chain unsaturation influenced the ability of the lipid to emulsify
tricaprylin (glyceryl trioctanoate). PCs having shorter and saturated acyl hydrocarbon
chains were more effective emulsifiers as they produced emulsions with smaller mean
globule size with less change in appearance and droplet size over time.
Lipid emulsions are often co-emulsified with a biocompatible synthetic
surfactant to enhance emulsffication properties. An example of an oil requiring co
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emulsification is vitamin E. Previous studies have shown that stable tocopherol
emulsions cannot be prepared with lecithin as the sole emulsifier [72]. A possible
explanation for this observation is the greater polarity of tocopherol compared to
vegetable oils due to the presence of a hydroxyl group on the aromatic ring. The
enhanced polarity of tocopherol may solubilize more lecithin in the emulsion core
resulting in less emulsifier at the interface to stabilize the system. Consequently, a
more hydrophilic co-emulsifier is required to emulsif’ tocopherol. The synthetic
surfactants approved for intravenous injection are few and include polysorbates,
cremophors and poloxamers.
To aid in the initial selection of emulsifiers, the hydrophile-lipophile balance
(HLB) method is widely used. HLB is a system which classifies surfactants on an
f
arbitrary scale based on the relative proportions of the hydrophilic and hydrophobic
parts on the moiecule. Each surfactant is given anumber usuaiiy between O and 20. If
the HLB value is high, the surfactant has a relatively large number of hydrophilic
groups and is more soluble in water. In contrast, surfactants with low HLB are more
hydrophobie and will consequently be more easily dispersed in organic phases. In
general, stable w/o emulsions are formed from surfactants with low HLB, whereas
those with high HLB are typically used to make stable 07w emulsions. HLB values
for several synthetic emulsifiers that are approved for intravenous injection are listed
in Table 5. The HLB method also classifies the oil, but in terms of HLB “required”
(HLBrequired). The HLBrequired specifies the HLB of the emulsifier that will produce the
most stable emulsion. Oils are usually given two HLBrequjred values, one to produce a
stable 07w emulsion and the other for a stable w/o emulsion. This method allows the
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formulator to match the HLB of the emulsifiers with the HLBrequireu of the ou to
produce a stable emulsion. The HLBrequired values to produce a stable 01w emulsion
for cottonseed oil, safflower ou and soybean oil are 7.85, 7.72 and 7.66, respectively
(Crodamol catalogue).
The HLB concept is advantageous in the initial screening stage of emulsion
development as it reduces the number of emulsifiers to consider for a given type of
ou. Although, the formulator should be aware that the HLB method has serious
limitations, which arise from the fact that only the molecular structure of the
individual surfactant is considered and the emulsion as a whole us ignored [8J. for
instance, the HLB method does flot take into account pertinent factors such as the
conformation of the surfactant, the salinity of the aqueous phase or temperature [$0].
Consequently, even if HLB and HLBrequired are correctly matched the emulsion
produced may flot be stable.
Aqueous phase
The isotonicity of an injectable emulsion is important in order to avoid disturbing
the state of ceils in contact with the formulation. The final osmolarity should be
between 200 and 300 mOsm kg’ and can be achieved by adding isotonizing agents
such as glycerol, sorbitol and xylitol to the aqueous phase. Glycerol is more
commonly used and can be found in most parenteral emulsions including Intralipid®,
Lipofundin N®, Liposyn® and Soyacal®. Tonic agents such sodium chloride cari also
adjust osmolarity, however, they should be avoided as the ions can destabilize
emulsions (see earlier). The pH ofthe final emulsion may need to be adjusted and this
can be done by adding small amounts of HC1 or NaOH. The desired pH is usually
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between 7 and 8 in order to maintain physiological compatibility and minimize
hydrolysis of the ou and phospholipids [$1].
Antioxidants are ofien added to the emulsion to eliminate or reduce oxidation
of the drug, ou and emulsifier [8, 67]. Common antioxidants used for injectable
formulations include Œ-tocopherol, deferoxamine mesylate and ascorbic acid [$1].
The formulation may also require the use of preservatives to resist against microbial
growth. Microorganisms may change the physicochemical properties of the emulsion,
such as color, odor, pH and physical stability, and may present a health hazard [8].
Common preservatives used in injectable preparations include phenol, cresol and
methyl, ethyl or propyl esters ofpara-hydroxybenzoic acid [82].
5.2. Emulsion preparation
(Z The most common process to manufacture emulsions is to incorporate the
drug during the emulsification of the oil [66]. Another method to incorporate the
active ingredient is to add a sterilized solution of the drug dissolved in a solvent to a
pre-formed and sterilized emulsion. This method is not often done due to stability
issues that may be encountered such as drug precipitation in the aqueous phase and
emulsion cracking [1, 4]. The first step in emulsion preparation is usually to dissolve
the water-soluble components (isotonizing agent and preservatives) in the aqueous
phase and the lipophilic compounds (drug and perhaps the antioxidant) in the ou
phase. The emulsifier can be dispersed in either phase. Both phases are typically
heated and agitated to facilitate the dispersion ofthe various components [67]. The ou
phase is then added to the aqueous phase. As the oil is added, the mixture is agitated
with the aid of a medium-shear mixer and is usually heated. The rate of addition
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should be optimized because adding the ou phase two quickly can lead to incomplete
dispersion of the ou in the aqueous phase [67]. The temperature and duration of
heating in the premix stage depends largely on the thermosensitivity of the drug, ou
and emulsifier(s). This premix stage produces a coarse emulsion and can have a
substantial impact on the final product [66]. A premix that is uniform with a droplet
size under 20 jim, generally produces a final emulsion that is more unimodal and
physically stable [66]. Following the premix stage, droplet size must be decreased to
less than 5 tm in diameter and preferably below 1 jim, to avoid blocking the
capillaries of the lungs. To produce emulsions with small droplet size
microfluidization or high-pressure homogenization are usually used.
Microfluidization is a process whereby a liquid mixture is forced by high pressure
through an interaction chamber, which spiits the stream in two and then recombines
them at ultrahigh velocities [$3]. The product can then be recycled to reduce droplet
size further. The combination of high shear, turbulence and cavitation generated by
this apparatus can produce submicron emulsions with a narrow size distribution [84].
In high-pressure homogenization, fluid is forced at high pressure by means of a
plunger pump through a very nanow channel. Depending on the type ofhomogenizer
the fluid may then collide head-on with another high velocity stream or hit a hard
impact ring. Droplet size is reduced by cavitation, high-shear forces and high-speed
collisions with other droplets [85]. Pressure, temperature and number of passes are
parameters that can be controlled and influence the efficiency of droplet size
reduction.
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Afier the desired droplet size is achieved, the formulation is filtered to remove
large droplets or debris and sterilized. Sterilization can be achieved by autoclaving or
by filtration through a 0.22 jim cartridge filter. The heat generated by autoclaving can
cause the ou and lecithin to hydrolyze liberating free fatty acids, which will reduce
the pH ofthe formulation. The conditions for sterilization by autoclaving will need to
be selected careftilly to minimize the degradation of heat sensitive products. filter
sterilization on the other hand greatly reduces the heat burden on the emulsion [67].
Not all emulsions can be sterilized by filtration, as a mean droplet size Iess than 200
nm is an essential requirement. Large droplets may clog the 0.22 tm cartridge filter
and prevent sterile filtration [86]. The main manufacturing steps involved in the
production of intravenous emulsions are outlined in f igure 10.
5.3. Emulsion characterization
Injectable emulsions are ofien characterized for mean droplet diameter, size
distribution, surface charge and phase inversion temperature. The aforementioned
properties are useful in predicting emulsion stability, biocompatibility and in vivo
biodistribution. Control over droplet size and size distribution can impart some
specificity towards target tissues and are also important predictors of biocompatibility
as droplets greater than 5 tm can potentially form pulmonary emboli. The maximum
allowable droplet size for intravenous administration, however, is unclear. Emulsions
containing few droplets above than 5 im might not necessarily cause any adverse
reaction since capillary blockage may be reversible by droplet degradation and large
droplets may pass through small capillaries by deforming [$7]. Burnham et al. [8$]
found that fat droplets greater than 7.5 .tm in diameter could deform and pass through
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pulmonary vasculature without difficulty. There are a number of techniques available
to measure mean droplet size and size distribution of emulsions. Dynamic light
scattering (also known as photon correlation spectroscopy or quasielastic light
scaftering), atomic force microscopy, static light scattering (or intensity light
scattering) and electron microscopy are frequently used to determine the size and size
distribution for droplets below 1 im [3$, $9]. However, apart from atomic force
microscopy and electron microscopy, the upper limit of detection on these
instruments prevents the evaluation of the droplet size distribution above 5 pm. for
detection of droplets greater than 5 im, light obscuration, electrical-sensing zone
(Coulter Counter) and optical microscopy are appropriate methods [90-92].
Surface charge measurements are also useful indicators of emulsion
biocompatibility. Surfaces with a net positive charge are more likely to aggregate in
the blood stream in the presence of plasma proteins than negatively-charged or
neutral droplets. Charged surfaces can also impart physical stability to the emulsion
by prevented/reducing coalescence upon random collisions through electrostatic
repulsion (see earlier). The surface charge of an emulsion droplet can be obtained
through zeta potential measurements using laser Doppler anemometry [93]. Lastly,
phase inversion temperature, the temperature at which the emulsion changes from olw
to w/o or vice versa, can be a useful predictor of emulsion stability during
temperature altering processes such as heating, emulsification and sterilization [94].
5.4. Stability measurement
The stability of an emulsion formulation is vital for its use in clinical
applications. The formulation must display physical, chemical and microbial stability
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for at least one year, if flot more. The difficulty in emulsion formulation is that the
system must be stable in aqueous solution, as opposed to polymeric micelles [95] or
nanoparticles [96] which can be easiiy stored as a lyophuiized powder whereby they
have less opportunity to destabilize. Creaming and a visible layer of oil are classic
signs of a physically unstable emulsion, while formulation discoloration is a typical
indication of chemical instabiiity. A long-term stability testing schedule should be
performed on ail promising formulation candidates, whereby each emulsion is stored
at various temperatures ranging from 4 to 40 °C. The emulsions should be monitored
for changes in size, pH, drug content, zeta potential, viscosity, electrical conductivity
and chemical composition [$1].
Physicat stabitity
The long-term stability of an emulsion is difficult to estimate and only time
can actually teil you whether the formulation is stable. Waiting for extended periods
of time to find out whether a number of formulation efforts are stable is very
impractical and there are methods available to accelerate stability testing. Most
accelerated tests induce physical instability by increasing the number of collisions
between globules. Accelerated tests based on sample heating, however, are not
reliable as they do not reflect the environment of samples kept under storage
conditions. Heating the sample not only enhances collisions but also diminishes the
protective action of adsorbed surfactants, increases the solubility of ail components,
promotes the degradation of heat sensitive products, alters the electric double-layer
and reduces surfactant adsorption at the emulsion interface, which can cause a
potentially stable emulsion to destabilize, leading to erroneous resuits [2, 81].
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Steam sterilization is considered an acceptable temperature raising accelerated
test as it approximates the environment that an emulsion would experience during
autoclaving. Excessive shaking and freezing and thawing cycles are other commonly
used accelerated stability testing processes as these techniques predict the conditions
that a formulation will be subjected to during transportation and storage [$1]. Another
good method to estimate emulsion stability is to make size measurements frequently
several weeks after the formulations are prepared. Emulsions that increase in size
over time during the first few weeks in storage will invariably destabilize [2]. If there
is no change in size, the formulator can have some hope that the emulsions will be
physically stable long term [2].
Chemicat stabitity
Injectable emulsions can undergo chemical changes by oxidation and
hydrolysis of the oil and/or emulsifier [67]. Chemical instability can be detected by
formulation discoloration and by changes in pH due to the increase in free fatty-acids.
Chemical instability can be reduced by storing the emulsions reftigerated, protected
from light and in sealed containers with a layer of an inert gas, typically argon. These
precautionary methods will reduce hydrolysis of the ou and emulsifier(s) [67].
Degradation of the encapsulated drug can also occur during storage. Consequently,
the integrity ofthe encapsulated drug over time must also be determined [67].
Some groups have investigated storing lipid emulsions as a lyophilized
powder to overcome some of the stabilized issues encountered when stored in
solution [97, 98]. freeze-drying emulsions, however, is difficult as the droplets may
crack during the lyophilization process and is rarely done. Bensouda et al. [99]
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evaluated the influence of a number of cryoprotective agents (glucose, mannitol,
sorbitol, maltose, lactose, glycin and dextran) on the success of the freeze-drying
process. Glucose, maltose, sorbitol and lactose provided protection against changes in
particle size, while mannitol, dextran and glycin offered no protective action.
6. Lipïd emulsions for the delivery of nucleic acid-based
drugs
Gene therapy is the science in which nonfunctional genes are substituted,
altered or supplemented for the treatment of genetic or acquired diseases. The
difficulty in the successful application of gene therapy is the complexity of delivering
functional genetic material such as plasmid DNA, antisense oligonucleotides (ODN)
or small interfering RNA into the cell. This is a result of their rapid degradation in
plasma and their inability to cross cell membranes due to their hydrophilic and
polyanionic .nature, and relatively large size. Viral vectors have been extensively
investigated for gene delivery [100]. However, concems over host inflammatory and
immune responses have created a demand for non-viral vectors [101-103]. As such,
cationic liposomes are commonly investigated because they enhance transfection of
DNA into the cell [104, 105]. Nonetheless, a major shortcoming ofthis technology is
the formation of large aggregates with time and the reduced transfection of the
liposome/DNA complex in the presence of serum [106].
Cationic lipid emulsions have been considered as alternative non-viral gene
delivery vectors to liposomes. Complexation occurs through electrostatic interactions
between the nucleic acids and the cationic lipid emulsifiers. The lipid emulsionlDNA
complex can be prevented from forming large aggregates in the presence of serum by
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co-emulsification with an appropriate non-ionic surfactant [107]. Yi et al. [10$]
prepared a cationic lipid emulsionlDNA complex that retained greater than 60%
transfection efficiency in the presence of 90% v/v serum. This formulation was
composed of soybean ou, 1 ,2,-dioleoyl-sn-glycero-3-trimethylammonium propane
(DOTAP) as the cationic surfactant and co-emulsified with 1 ,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) and 1 -palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine-N-[PEG 2000] (PEG2000POPE). The relatively high
transfection efftciency of the lipid emulsionlplasmid DNA complex can be attributed
to its ability to resist aggregation in the presence of serum, which may be due to steric
stabilization by the PEO chains of PEG2000POPE. Indeed, Kim et aI. [109] observed
that adding a co-emulsifier containing a PEO chain such as polysorbate $0 or the Brij
series (PEO 4, 7, 10 or 23 lauryl ether) produced DNA-complexed emulsions that
could resist changes in size in the presence of serum. In contrast, surfactants without a
PEO group such as sorbitan monooleate (Span $0), mannide oleate (Montanide $0)
and oleyl alcohol aggregated in the presence of serum and during DNA complexation.
The authors also observed that the presence of PEO in both polysorbate $0 and Brij
interfered with the electrostatic interactions between DNA and the emulsion interface.
DNA and cationic lipid interactions were reduced when the polysorbate 80 content or
PEO chain length in the Brij series increased. Despite the progress, much stili needs
to be done for the successful application of cationic emulsions to deliver genetic
material in vivo. Indeed, cationic lipid emulsions will most Iikely face the same
problems as other non-viral gene delivery systems.
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7. Conclusions
Lipid emulsions are promising carriers for highly lipophilic drugs due to their
biocompatibility, reasonable sheif-life, aptness for large scale manufacture and ability
to solubilize large quantities of drug in their oily core. Lipid emulsions can also alter
the biodistribution of incorporated drugs and enhance specificity towards target
tissues by passive and active methods. Evading the MPS or natural fat metabolism is
necessary when the encapsulated drug is to be delivered to non-MPS organs or liver
parenchymal ceils, respectively. Long-circulating lipid emulsions can be obtained by
reducing droplet size and by grafiing long-chain hydrophilic polymers, such as PEO,
to the emulsion interface. Moreover, active targeting using ligands that recognize
specific determinants on celis can enhance specificity and uptake by target ceils. It
should be kept in mmd that control over droplet biodistribution aJonc will not
enhance the therapeutic effect as the drug may leak out of the carrier before reaching
the target site. In general, drugs with higher lipophilicities (log P > 9) are retained
better within the emulsion afier intravenous administration. In addition to being
carriers for lipophilic dnigs, lipid ernulsions have also been adapted to deliver genetic
material and are an alternative non-viral vector to liposomes.
Several therapeutic lipid emulsions are commercially available for clinical use
and other formulations are presently undergoing clinical trials. The use of intravenous
lipid emulsions in the clinic will expand as new and less toxic formulations are
discovered.
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Tables
Table 1: Several commercially available emulsions for intravenous injection
Product Drug Manufacturer Indications
Diazemuls Diazepam Pfizer and Pharmacia Anti-convulsive,
sedative, muscle
relaxant
Diazepam®Lipuro Diazepam B. Braun General anesthesia
Diprivan®* Propofol AstraZeneca General anesthesia
Etomidate®Lipuro Etomidate B. Braun General anesthesia
Limethason® * Dexamethasone pamitate Mitsubishi Rheumatoid arthritis
Pharmaceutical
Liple® (Lipo-PGE1) Prostaglandin E1 (PGE1) Mitsubishi Vasodilator, platelet
Pharmaceutical inhibitor
PropofolLipuro® Propofol B. Braun General anesthesia
Lipo-NSAID® - Flurbiprofen axetil Kaken Pharmaceuticals Pain reliever
Ropion®*
Vitalipid * Vitamins A, D2, E, K1 fresenius Kabi Parenteral nutrition
*Based on the formulation oflntralipid® (10 or 20% soybean ou; 1.2% egg lecithin; 2.5% glycerol)
Table 2: Some intravenously injectable emulsions in development and in clinical
trials
Drug Product Name Indications ClÏnÏcal* Ref.
Aclacinomycin A Cancer chemotherapy
-
[110]
Amphotericin B Treatment offungal
- [97, 98]
infections
Beta-elemene SDP-1 11 Cancer chemotherapy
- [1111
Cyclosporine A - Immunosuppressant
- [112]
Docetaxel SDP-014 Cancer chemotherapy
- [111]
Perfluorooctyl Imavist® Ultrasound contrast agent Phase III [113]
bromide
Paclitaxel TOCOSOLIS- Cancer chemotherapy Phase III [72]
$184
Paclitaxel SDP-013 Cancer chemotherapy
- [1111
Perfluorooctyl Oxygent® Artificial blood substitute Phase III [7$]
bromide
Propofol Ampofol® General anesthesia Phase III [114]
Sedation
Propofol IDD-D propofol General anesthesia Phase III [1151
Sedation
Alpha-tocopherol SDP-1 12 Cancer chemotherapy
- [1111
succinate
Vincristine Cancer chemotherapy - [116]
Status as ofMarch 2006
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Table 3: Antitumor activity of RS- 1541 emulsion formulations against M5076
sarcoma at the MTD
Mean Dose Tumor Tumor Growth I.L.S.’ Cure
Diameter (MTD)2 DÏameterb (%) Delayc (day) (%) (on day 120)
(nm) (mg/kg)
Surfactant 6.0 213 17 62 0/6
solution
70 4.5 166 24 66 0/6
100 4.5 113 29 69 0/6
220 15.0 13 >61 >224 4/6
380 40.0 18 56 >195 3/6
a RS-1541 was given in each formulation to M5076 bearing BDFI mice via a single i.v. injection at
MTDs on day 13 aller inoculation (6 mice were used for each group).
b Tumor diameter on day 44 divided by that on treatment day.
C Days required for the tumors to reach again the diameter on treatment day following a therapy.
d Increase in life span: ratio (%) of median survival days in a freatment group of mice to that in the
control group (37 days).
Adapted with permission from Springer Science and Business Media Ref. [401 Copyright 1996
Table 4: List of oils used in commercial emulsions for parenteral nutrition
Oils Commercial Product name Manufacturer
LCTs
Cottonseed oit Lipofundin® B. Braun
Safflower oil Liposyn® Abbott Laboratories
Soybean ou Intralipid® Kabi-Pharmacia
Soyacal® Alpha Therapeutics
Travamulsion® Travenol Laboratories
Liposyn 1II® Abbott Laboratories
Lipofiindin S® B. Braun
Trivé 1000® Egic
Safflower oil:Soybean ou Liposyn II® Abbott Laboratories
LCTs + MCTs
Soybean oil:MCTs, (1:1) Lipofundin® MCT/LCT B. Braun
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Table 5: Several non-phospholipid surfactants approved for intravenous
administration in at least one country or under clinical investigation
Chemïcal Name Common Names Properties MW Ref. HLB Ref.
Poly(ethylene oxide) 35 Cremophor EL Non-ionic 2515 [117] 13.5 [1181
castor ou
Poly(ethylene oxide) 40 Cremophor RU 40 Non-ionic NIA - 14-16 [1191
castor ou
Poly(ethylene oxide) 60 Cremophor RU 60 Non-ionic N/A - 15-17 [1191
castor ou
Poly(ethylene oxide) 20 Polysorbate 20 Non-ionic 1225 [120] 16.9 [120]
sorbitan monolaurate
Poly(ethylene oxide) 20 Polysorbate 40 Non-ionic 1282 [120] 15.6 [120]
sorbitan monopalmitate
PoIy(ethylene oxide) 20 Polysorbate 80 Non-ionic 1310 [121] 15.0 [120]
sorbitan monooleate
pEO80bppO27bpEO80a Poloxamer 188 Non-ionic 8400 [1221 29 [118]
pEo101-b-PP056-b-PE0101 a,b Poloxamer 407 Non-ionic 12600 [123] 22 [124]
d-a-tocopheryl polyethylene TPGS Non-ionic 1513 [121] 13 [72]
glycol 1000 succinateb
Poly(ethylene oxide)-15- Solutol US-15 Non-ionic 958 - 14-16 -
hydroxystearate
Deoxycholic acid - Anionic 392 - 24 [72]
Glycocholic acid - Anionic 465 - N/A -
Poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)
b In Phase III clinical trials
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Dietary fat
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Liver parenchymal ceNs
figure 3 Absorption and metabolism of dietary fat. Dietary fats are metabolized and
incorporated into chylomicrons in the small intestine. Then, chylomicrons enter the
blood circulation via the thoracic duct. During circulation, the triglycerides of
chylomicrons are rapidly hydrolyzed via lipoprotein lipase (LPL) on endothelial
surfaces, then chylomicron remnants are produced. finally, chylomicron remnants are
cleared by the liver by the LDL or remnant receptors. TG, triglyceride; Chol,
cholesterol; AI, apolipoprotein AI; AIV, apolipoprotein AIV; B4$, apolipoprotein
B4$; CII, apolipoprotein CII; E, apolipoprtoein E. Reprinted with permission from
Elsevier Ref. [13] Copyright 2000.
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Figure 4: Effect of particle size on the clearance of cholesteryl oleate (CO) label
from plasma as a function of time afier intravenous administration into mice. The
emulsions were composed of triolein (TO): 1 ,2-dipalmitoyl-sn-glycero-3-
phosphatidylcholine (DPPC):polysorbate $0: polyethylene glycol modified 1,2-
dipalmitoyl-sn-glycero-3 -phosphatidylethanolamine (PEG2000-DPPE) (2:1:0.4:0.1,
w/w) . The droplet sizes ofthe emulsions injected were 50 (o), 100 (o) and 175 nm
(A). Adapted with permission from Elsevier Ref [2$] Copyright 1996.
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Figure 6 : Radioactivity in plasma of triolein (TO) and cholesteryl oleate (CO) labels
afier injection of emulsions stabilized by mixtures of sphingomyelin (SM) with egg
phosphatidylcholine (egg PC). TO-CO-cholesterol emulsions stabilized with mixtures
of SM and egg PC were injected intravenously in conscious rats. Plotted are the data
for labeled TO (A) and CO (B) incorporated in the emulsions remaining in the plasma
at 3, 5, 8, 12 and 20 min after injection. Resuits are means ± S.E. of at least four
experiments for each observation. SM 100% (.), SM/egg PC 50/50 (À), SM/egg PC
25/75 (A), egg PC 100% (o). Adapted with permission from Elsevier Ref. [21]
Copyright 1992.
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figure 7: Radioactivity in the liver and spleen of triolein (10) and cholesteryl oleate
(CO) labels after injection of emulsions stabilized by mixtures of sphingomyelin
(SM) with egg phosphatidylcholine (egg PC). TO-CO-cholesterol emulsions
stabilized with mixtures of SM and egg PC were injected intravenously in conscious
rats. Organ uptakes of radioactive TO and CO labels in the emulsions were measured
20 min after injection. Results are means + S.E. of at least four experiments for each
observation. By analysis of variance the differences between groups were statistically
significant with P <0.01 for liver TO, P < 0.00 1 for liver CO, P < 0.01 for spleen TO
and P < 0.025 for the spleen CO. Adapted with permission from Elsevier Ref. [21]
Copyright 1992.
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Figure 8: Blood concentration-time profile of stealth liposomes and different lipid
nanocapsule formulations prepared by the conventional (A) or post-insertion method
(B). Mean ± SD (n =3 to 5). A: PEGylated liposomes (.), plain lipid nanocapsules
(o), PEGylated lipid nanocapsules with 1.7 mol% 1 ,2-distearoyl-sn-glycero-3-
phosphatidylethanolamine-N-monomethoxy-[polyethylene glycol] (PEG2000-DSPE)
(u), PEGylated lipid nanocapsules with 1.4 mol% PEG5000-DSPE (Â), and
PEGylated lipid nanocapsules with 3.4 mol% PEG2000-DSPE (+). 3.- PEGylated lipid
nanocapsules with 6 mol% PEG2000-DSPE (.), PEGylated lipid nanocapsules with 6
mol% PEG5000-DSPE (o), and PEGylated lipid nanocapsules with 10 mol% PEG2000-
DSPE (Â). Formulations were injected intravenously at a dose of 2 mg lipids/rat.
Adapted with permission from Springer Science and Business Media Ref. [38]
Copyright 2004.
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Figure 9: Liver uptake and serum decay of the control and human recombinant (rec)
apo E-enriched emulsion-iododeoxyuridine-oleoyl ([3H]IDU-012) in rats, in the
absence or presence of lactoferrin. Control and rec-apo E-enriched emulsions,
double-labelled with [1-’4C]cholesteryl oleate ([‘4C]CO) and [3H]IDU-012 were
injected into fasted anaesthetized rats. A, B, C: At the indicated times, the liver
uptake and serum decay of [‘4C]CO (A) and [3H]IDU-012 (B) were determined. The
liver uptake and serum decay of rec-apo E-enriched emulsions were also determined
after preinjection of lactoferrin (C). D. At 30 min afier injection of emulsion-rec-apo
E-IDU-012, the liver was perfused. Total liver (L) association was determined and
parenchymal (PC), endothelial (EC), and Kupffer (KC) celis were subsequently
isolated. Values are means + s.d. of three experiments. Adapted with permission
from Macmillan Publishers Ltd. Ref. [60] Copyright 1995.
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PremÉx Stage
(Production of a Coarse Emulsion)
High Energy Emulsification
(Droplet Sïze Reduction)
pH Adjustment
(Usually Between 7 and 8)
1
Filtration
(Removal cf Large Droplets and Debris)
Packagîng
Autoclavïng
(Heat Sterilization)
figure 10: The main manufacturing steps involved in the production of intravenous
emulsions.
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1. Abstract
Purpose. The purpose of this study was to develop long-circulating emulsions and
evaluate their ability to target neoplastic tissues. Methods. Nano-sized emulsions (100
— 120 nm) composed of tricaprylin (TC)/polysorbate 80 (PS-80)/hydrogenated
soybean phosphatidylcholine (HSPC) and TC/PS-80/egg sphingomyelin (ESM)
(5:3:1, w/w) were prepared by probe sonication. They were incubated with various
poly(ethylene glycol)-distearoylphosphatidylethanolamine derivatives (DSPE-PEG)
including DSPE-PEG 2000, DSPE-PEG 5000 and D$PE-N-[(pentaerythritol
polyoxyethylene) glutaryl] (DSPE-4-armPEG) (PEG MW 2000). The effect of ESM,
D$PE-PEG 2000 concentration and various D$PE-PEG derivatives in prolonging
circulation time and enhancing accumulation into neoplastic tissues was assessed in
vivo in mice bearing subcutaneously implanted B 16 melanoma or C26 colon
adenocarcinoma. Resutts. No significant differences were detected between TC/PS
80/HSPC and TC/PS-$0/ESM emulsions in vivo. Only emulsions coated with either
PEG 2000 or 5000 had prolonged circulation time in blood and were able to
accumulate significantly into solid tumors. Emulsions grafied with DSPE-4-armPEG
were removed quickly from blood despite the 2000 MW PEG segment. The ability of
the long-circulating emulsions to extravasate at the tumor site depended on the tumor
model, whereby the C26 tumors were more permeable to the emulsions than B16.
Conclusion. Incorporating single-chain PEG 2000 or PEG 5000 at the interface
significantly prolonged the residence time of emulsions in blood and enhanced their
ability to target solid tumors. Such nano-sized emulsions could potentially improve
the delivery of incorporated anticancer drugs to neoplastic tissues.
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2. Introduction
One of the major difficulties in cancer therapy is to achieve good specificity
of antineoplastic agents for their target site(s). As a resuit of their toxicity towards
healthy tissues, many anticancer drugs are ofien administered at doses that are
subtherapeutic. Over the past three decades, a great deal of research has been devoted
to altering the pharmacokinetics and biodistribution profiles of these drugs by
encapsulating them in colloidal drug carriers such as liposomes [1], nanoparticles [2]
and polymeric micelles [3]. These nanoscopic systems can enhance drug
accumulation at the tumor site and reduce distribution to healthy tissues, provided
that the encapsulated cargo remains associated with the carrier afier intravenous (i.v.)
injection [4, 5]. One method in which drug carriers achieve this selectivity is by the
enhanced permeation and retention (EPR) effect, which exploits the difference in
capillary structure between healthy and cancerous tissues [6]. Tumor vasculature is
generally porous or “leaky” allowing enhanced permeation of colloidal particles
across the endothelium and into the extravascular space. Moreover, tumors have poor
lymphatic drainage allowing colloids to be retained in the tissue for prolonged periods
of time [7, 8]. For successful accumulation into the tumor by the EPR effect, the
concentration of drug carrier in the blood must remain high for more than 6 hours [7].
However, afler intravenous administration, colloidal drug carriers are usually
recognized as foreign bodies and are rapidly taken up by circulating monocytes and
macrophages in the liver, spleen and bone mai-mw. The ability of colloidal particles
to evade the mononuclear phagocyte system (MPS) and exhibit long residence times
$1
in blood depends largely on carrier size and the physicochemical properties of the
surface.
Modifying the colloid surface with a hydrophilic and flexible polymer such as
poly(ethylene glycol) (PEG) is widely used to prolong circulation time [9-il]. The
!ongevity of PEGylated colloids is attributed to the highly hydrated and flexible PEG
chains, which reduces interactions with plasma proteins and ce!! surfaces [12, 13].
Incorporating sphingomyelin ($M) at the interface is another approach that has been
shown to enhance the systemic circulation time of emu!sions and liposomes [14, 15].
For examp!e, Takino et al. [15] reported that adding SM to an egg
phosphatidylcholine (PC) emulsion prolonged circulation time and decreased uptake
by the MP$ organs. Similarly, Redgrave et al. [14] demonstrated that increasing the
proportion of $M to PC further enhanced circulation time and resulted in a
corresponding decrease in liver uptake. Moreover, liposomes composed of
SM/cholesterol (Chol) (5 5/45, molar ratio) were shown to prolong the half-life of
encapsu!ated vincristine, ciprofloxacin and vinorelbine [16-19]. In fact, this SM/Chol
formulation with encapsulated vincristine was evaluated in Phase III clinical trials
[20]. SM confers circulation longevity to emulsions and liposomes by enhancing
membrane rigidity, resulting in lower membrane permeability and greater stability in
vivo [21-24]. This membrane rigidifying effect of SM is a result of its high content of
saturated acyl chains relative to naturally occurring PCs and its ability to form
intermolecular hydrogen bonds [21, 25].
Among the various drug delivery systems for cancer therapy, emulsions are
promising carriers due to their biocompatibility, reasonable stabi!ity, ability to
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solubilize large quantities of lipophilic compounds and relative ease of manufacture
at an industrial scale [26, 27]. Despite the vast amount of literature available on
emulsions as carriers for anticancer drugs, flot much work has been devoted to
characterizing the accumulation of the droplet itself into solid tumors. The purpose of
this study was to develop long-circulating emulsions using pharmaceutically
acceptable excipients and evaluate their ability to target neoplastic tissues. The
influence of egg SM (ESM) and distearoylphosphatidylethanolamine (DSPE)-PEG
concentration and structure in prolonging circulation time and enhancing
accumulation into solid tumors was assessed in mice bearing subcutaneously
implanted B 16 melanoma or C26 colon adenocarcinoma.
3. Materials and methods
3.1. Materials
Hydrogenated soybean phosphatidylcholine (HSPC, >99% PC), egg
sphingomyelin (ESM) and 1 ,2-distearoyl-sn-glycero-3-phosphatodylethanolamine-N
monomethoxy-[PEG 2000] (DSPE-PEG 2000) were purchased from Northern Lipids
Inc. (Vancouver, BC, Canada). Tricaprylin (TC) and poly(ethylene oxide) 20 sorbitan
monooleate (jolysorbate 80, PS-$0) were obtained from Sigma-Aldrich (Oakville,
ON, Canada). DSPE-PEG 5000 was bought from Avanti Polar Lipids Inc. (Alabaster,
AL) and DSPE-N-[(pentaerythritol polyoxyethylene) glutaryl] (DSPE-4-armPEG)
(PEG MW 2000) was from the NOF Corporation (Tokyo, Japan). [3H]-Cholesteryl
3 . . .hexadecyl ether ([H]-CHE, 51.0 Ci/mmol), Hionic-fluor , Soluene 350 and
Solvable® were obtained from Perkin Elmer (Woodbridge, ON, Canada). Sodium
chloride (0.9% w/v) injection USP was purchased from B. Braun Medical Inc. (Irvine,
$3
CA). Ail products mentioned above were used without fiirther purification.
Chloroform and hexane (purification grade), purchased from Sigma-Aldrich Canada
Ltd. (Oakville, ON, Canada), were further purified by filtration through drying
columns on a PureSolv system (Innovative Teclmology Inc. system, Boston, MA) and
distilled prior to use. Ethanol was obtained from Commercial Alcohols Inc.
(Brampton, ON, Canada) and distilled. Water was deionized with a MilliQ®
purification system (Millipore, Bedford, MA).
3.2. Compression isotherms
Surface pressure - molecular area (it-A) isotherms of HSPC, ESM, PS-$0,
H$PC/PS-$0 and ESM/PS-80 were measured with a Langmuir-Blodgett trough (300
x 200 x 5 mm) from Nima Technology (Coventry, England). Surface pressure was
determined by means of a Wilhelrny plate attached to a microbalance. The subphase
was a phosphate buffered saline (PBS, pH 7.4) composed of 75 mM sodium chloride,
53 mM sodium phosphate dibasic, and 13 mM sodium phosphate monobasic, filtered
through a O.22-irn membrane. The temperature of the subphase was maintained at
25°C with a thenuostated, circulating water bath. Solutions of HSPC and E$M were
prepared at a concentration of 1 mg/mL in chloroform and hexane:ethanol (95:5, v/v),
respectively. f ifiy microliters of solution were deposited dropwise at the air/water
interface using a microsyringe. For PS-80, dissolved in chloroform (0.25 mglmL), 20
j.iL of solution were spread on the subphase. In the case of the mixed monolayer
isotherms (0.25 mg/mL total amphiphiles), 20 jiL of HSPC/P$-$0 (1:3, w/w)
dissolved in chloroforrn and ESM/PS-80 (1:3, w/w) prepared in hexane;ethanol (95:5,
v/v) were deposited. The films were compressed at a constant barrier speed of 8
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cm2fmin afier initial delay periods of 30 min and 1 h for lipids spread in chloroform
and hexane:ethanol, respectively. To reduce contamination from the atmosphere, the
entire apparatus was located in a closed Plexiglas cabinet.
from the it-A isotherms, monolayer compressibility at a given surface
pressure (n) was calculated using equation (1):
C = (-1/A)(dA/dn) (1)
where C5 is the modulus of compressibility and A represents the molecular area at a
particular surface pressure.
3.3. Preparation and characterization of emulsions
The emulsions were prepared by probe sonication using a Sonic Dismembrator
(model 550, fisher Scientific, Pittsburgh, PA). Prior to sonication, TC, PS-80 and
either ESM or HSPC were mixed together under magnetic stirring above the phase
transition temperature of ESM and HSPC (ca. 55°C) for 10 min. The dispersing phase
(0.9% NaC1 in water) was then added to the premix and the formulation was
heatedlmixed at 55°C for an additional 20 min. The volume was adjusted with 0.9%
NaC1 in water until the lipid phase represented 9% (w/v) of the emulsion. Afier the
premix step, the formulation was sonicated at medium intensity (80 W) for 40 s on
pulse mode (pulse every 2 s for 0.2 s). The composition of ou and emulsifier was
TC/PS-80/HSPC or ESM (5:3:1, w/w). PEGylated emulsions were prepared by
incubating an aqueous micelle solution of DSPE-PEG with a preformed ESM
emulsion for 1.5 h at 60°C. The amount of DSPE-PEG added to the emulsions
corresponded to either 10 or 15 mol% of the total surface components (exciuding
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TC). [3H]-CHE, a non-exchangeable lipid derivative, was incorporated into each
emulsion during emulsification to track the distribution of the entire droplet in vivo.
The mean hydrodynamic diameter and size distribution of the emulsions were
determined by dynamic light scattering with a Malvem Autosizer (Malvem
Instruments Ltd, Malvern, UK) at 25°C and a fixed angle of 900. Measurements were
performed in triplicate afier dilution ofthe emulsion in water.
3.4. Biodistribution studies
The in vivo experiments were performed on either C57BL16 mice (female, 18-
21 g) bearing 316-Fi O melanoma or Balb/C mice (female, 18-21 g) with C26 colon
adenocarcinoma. Animal care and handiing were approved by the Animal Welfare
and Ethics Committee of the University of Montreal in accordance with the Canadian
Council on Animal Care guidelines. The hair on the back and hind legs of the mice
were removed by shaving. The B 16 and C26 ceils were harvested by trypsinization,
resuspended in growth medium and injected subcutaneously in three separate
locations on the back of each mouse. for the 316 celis, approximately 1x1 ceils in
50 iL of growth medium were delivered per implantation site, while 2x106 of C26
celis in 50 tL were injected. The formulations were administered when the tumor
volume reached approximately 20 mm3. The volume (V) of each tumor was
calculated from equation (2):
V = 1/2(4it/3)(L/2)(W/2)H (2)
where L is the length, W is the width and H is the height.
The emulsions were prepared as described above and diluted with NaC1
(0.9%) for injection. The tumor-bearing mice were anesthetized with isofluorane and
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administered 5.4 mg of Iipids/mouse (exciuding DSPE-PEG) in a 100-jiL injection
volume via the subclavian vein. Each mouse received approximately 0.7 iCi [3H]-
CHE.
The mice (n=4-5 per group) were sacrificed at 2, 6 and 12 h post injection. At
each time point, the blood, tumor and organs of interest (liver, spleen, heart, lungs,
kidneys, and a piece of muscle) were extracted and assayed for [3HJ-CHE content.
Blood was sampled by cardiac puncture and placed into pre-weighed scintillation
vials. Excess blood was removed from the organs by passing a continuous flow of
0.9% saline through the systemic circulation via the heart. The tumors and organs of
interest were then harvested, wiped and weighed. The blood was digested in a
mixture of isopropanol/$oluene® (1:1 to 1:3 v/v) or isopropanol/$olvable® (1:1 to 1:3
v/v) at 60°C until complete solubilization. The samples were allowed to cool down to
room temperature and were then discoloured with hydrogen peroxide (F1202, 30% v/v)
in aliquots of 100 tL. The organs and tumor were dissolved in Soluene® or Solvable®
tissue solubilizers at 60°C until total digestion. Hionic-Fluor scintillation cocktail (10
mL) was added to the solubilized tissues and the samples were stored overnight at
4°C in the dark prior to counting. The amount of [3H]-CHE radioactivity in blood,
organs and tumor was assayed using a Beckman liquid scintillation counter (model
LS 6500, Beckman, fullerton, CA). The quenching of radioactivity due to the
digested tissues was corrected with a quench curve. The percent injected dose (ID) of
emulsions in blood was determined by assuming that the total mass of blood
represents 7.2% ofthe mouse body weight [28]. formulations were compared at each
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time point with a one-way analysis of variance followed by fisher’s post-hoc test.
The level of significance was ap value <0.05.
4. Resuits and discussion
4.1. Compression isotherms
The compressibility and molecular conformations of two high phase transition
lipids, HSPC and E$M, were characterized at the air/water interface using the
Langmuir balance technique. Isotherms of pure HSPC and ESM monolayers in PBS
buffer (pH 7.4, 25°C) are presented in Figure 1 lA. for clarity, only one isotherm for
each compound was selected from a series of reproducible profiles. The E$M
monolayer displayed a two-dimensional phase transition from liquid-expanded (chain
disordered) to liquid-condensed (chain ordered). This transition region can be seen
more clearly in Figure 11 B by the change in siope of the n-A isotherm, expressed as
the modulus of compressibility (see equation 1). The two-dimensional phase
transition is consistent with previous reports, however, the sharpness of the transition
region has been shown to vary depending on several factors including subphase
temperature, chain length and heterogeneity in acyl chain composition [29, 30].
Naturally occurring SMs such as bovine brain SM and ESM tend to broaden the
transition region compared to pure 18:0 $M and 16:0 SM, which are the main lipids
in bovine brain $M and ESM, respectively [29]. The broader transition is most likely
due to the heterogeneity in acyl chain composition, which would affect the
alignment/ordering of the chains. The H$PC film, on the other hand, did not undergo
an order-disorder transition like ESM. Instead, HSPC shifted from gas directly into a
highly ordered liquid-condensed phase and then to a collapsed regime (Figure 1 lA).
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HSPC formed a less compressible film at the air/water interface as indicated in Figure
113 by the lower the modulus of compressibility compared to ESM at ail surface
pressures. Another important difference between the molecules is that ESM could
form a more densely packed film at higher surface pressures. Indeed, above about 25
mN/m, the area occupied per moiecule was smaller for ESM than H$PC (Figure
liA).
The differences between HSPC and ESM moiecuies at the air/water interface
can be rationaiized by their structural discrepancies. Both ESM and H$PC share a
common zwitterionic phosphoryicholine headgroup, however, they differ in the
degree of chain unsaturation and in their abiiity to form hydrogen bonds. H$PC, like
other PCs, contains two acyl chains that are esterified to a glycerol backbone. These
acyl chains are approximately the same length, however, unlike most naturaiiy
occurring PCs, HSPC contains no unsaturations (major component is 16:0, 18:0). For
ESM, a saturated acyl chain is linked to a sphingosine tbrough an amide bond. The
greater compressibility of ESM may be due to the unsaturation present between
carbons 4 and 5 of the sphingosine, which could produce a more disordered and fluid
monolayer than HSPC. The HSPC moiecules are more ordered in the hydrophobic
region due to the long and completely saturated acyl chains and thus are iess
compressible in the liquid phase. These resuits are consistent with the findings of
Smaby et al. [29], whereby ESM was more compressible than a saturated PC with
long acyl chains, such as distearoyi-sn-glycero-3-phosphatidylcholine (DSPC) (18:0,
18:0), at ail surface pressures. In addition, E$M was more compressible than 1-
palmitoyl-2-stearoyl-sn-glycero-3
-phosphatidylcholine (PSPC) (16:0, 18:0) and 1,2-
$9
dipalmitoyl-sn-glycero-3 -phosphatidylcholine (DPPC) (16:0, 16:0) at surface
pressures above 5 and 10 mN/m, respectively [29]. Below these surface pressures,
PSPC and DPPC, were in a chain-disordered regime and were slightly more
compressible than ESM [29].
In addition to the differences in chain unsaturation, E$M has a much greater
hydrogen bonding capacity than HSPC due to the amide and hydroxyl groups, which
are flot present in phospholipids. The intra- and intermolecular hydrogen bonding
within and between ESM molecuies may facilitate a more condensed organization of
the head group region reducing the degree of hydration in the polar region and
allowing for denser packing of the molecules upon compression compared to H$PC.
These resuits are consistent with the findings of other group which report a lower
degree of head group hydration in SM containing monolayers and bilayers compared
withPCs [31-33].
The influence of PS-$0, a major component in the emulsion, on the phase
behavior of HSPC and ESM is illustrated in figure 12A. for ah isotherms, the
coilapse pressure was flot achieved. Consequently, the monolayers were compressed
until the minimum area of the trough was reached. In the presence of P$-80, HSPC
and ESM dispiayed gaseous and iiquid-phase behavior over the range of molecular
areas investigated. These mixed monolayers were more fluid and compressible than
pure HSPC and ESM films. The larger, more hydrated head group of PS-80
(poiy(ethyiene oxide) 20 sorbitan) wouid take up more space than phosphorylcholine
at the air/water interface, preventing close intermolecular contact. Ail three
monolayers exhibited similar compressibility (figure 12B), however, E$M/P$-$0
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formed a more denseiy packed film as indicated by the smaller surface areas occupied
by this mixture. A hypothesis proposed to explain this phenomenon is that ESM may
reduce head group hydration by intra- and intermolecular hydrogen bonding within
ESM molecules and between neighboring ESM molecules or with PS-80. As a resuit,
the reduction in hydration of the head group region could permit denser packing of
the molecules. In the context of injectable emulsions for drug delivery, incorporating
ESM into a formulation emulsified with PS-80 may potentially enhance circulation
time by the tighter molecular packing at the emulsion interface. Owing to the
interesting properties of ESMJPS-80 monolayers, we then investigated in vivo
whether E$M could enhance the circulation longevity of an emulsion coemulsified
with PS-$0.
4.2. Biodistribution studies
Oii-in-water emuisions with mean diameters ranging from 100 to 120 nm
were prepared by probe sonication (Table 6). The internai phase consisted of TC and
was emulsified with a combination of PS-$0 and either HSPC or E$M. The weight
ratio ofoil and emuisifier was kept constant at 5:3:1 (TC/PS-80/HSPC or ESM). TC
was chosen as the internal phase because medium chain triglycerides (MCTs) are
generaiiy better solubilizers for drugs than long chain triglycerides (LCTs) and thus
these emulsions could potentially be used to encapsulate drngs [34-36]. PS-$0 was
the main emulsifier since it is well tolerated for i.v. application and the high density
of short PEG segments at the emulsion interface may extend systemic circulation [37-
39]. Only emulsions prepared with ESM were incubated with various D$PE-PEG
derivatives. The final concentration of D$PE-PEG in the formulation represented 10
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to 15 mol% of the total surface components (exciuding TC). The presence of D$PE
PEG did flot considerably alter the mean size ofthe emulsion (Table 6).
The influence of ESM and DSPE-PEG 2000 in prolonging the circulation time
of emulsions was first assessed in C57BL/6 mice inoculated with B16 melanoma. b
track the distribution of the droplets in vivo, the emulsions were labeled with [3H]-
CHE. This marker has been commonly used for biodistribution studies since it is
highly lipophilic and non-exchangeable [40-42]. In this first experiment, three
different formulations were administered: TC/PS-$0/HSPC, TC/PS-$O/ESM and
TC/PS-80/E$M!(10 mol%)D$PE-PEG 2000. As shown in figure 13A, the non
PEGylated HSPC and ESM emulsions were quickly removed from the systemic
circulation with less than 10 % of the ID remaining in blood after 2 h. Emulsions
containing ESM circulated slightly longer in blood than HSPC, however, statistical
significance could not be demonstrated (p> 0.05). The slightly higher residence time
for the ESM emulsion may be attributed to a tighter monolayer at the interface, which
could potentiaÏly enhance the stabiÏity of the emulsion in blood. This tighter
monolayer, however, was insufficient to provide significant enhancement in
circulation longevity. As anticipated, figure 1 3A shows that PEGylation of the
TC/PS-80/ESM emulsion with 10 mol% PEG 2000 significantly prolonged
circulation time (p < 0.05). Two hours afier administration, approximately 35% ID
was still present in blood. Surprisingly, despite the long-circulating properties of the
PEGylated emulsion, all formulations showed similar accumulation into B16
melanoma tissues (Figure 1 3B). Afler 12 h, uptake into the tumor was between 1.2
and 2.2% ID/g of tissue. The comparable accumulation into the tumor for short and
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long-circulating emulsions may be a resuit of 10w pore cut-off size in the tumor
vasculature, restricting droplet extravasation across the vessel wall. Depending on the
celi une, tumors can have varied pore cutoff sizes, ranging from 200 nm to 1.2 tm
[431. Despite the limited distribution into B16 melanoma, ail emulsions accumulated
more in the tumor than in the muscle (Figure 13B and C). Our resuits for vector
distribution into the tumor are siightiy lower compared to long-circulating liposomes
( 100 nm in diameter) whereby accumulation into B 16 melanoma (inoculated
intramuscularly or in the hind footpad) was between 4.5 to 13.2% ID/g 24 h afler
injection [44]. The lower uptake of our PEGylated emulsions into B16 melanoma
may be due to differences in the site of tumor inoculation, the size of the tumor at the
time of injection and the time point at which the tumor was harvested. It was found
that tumor uptake increased 1 .7-fold, when liposome diameter was reduced from 13$
to 97 nm without any significant change in blood residence time, demonstrating the
importance of size on colloid extravasation into B 16 melanoma [44].
The effect of DSPE-PEG 2000 content (10 and 15 mol%) and different DSPE
PEG derivatives in prolonging circulation time was then explored in Balb/C mice
inoculated with C26 colon adenocarcinoma. In this study, five different formulations
were injected: TC/PS-$0/ESM, TC/PS-$0/E$M/(lOmol%)DSPE-PEG 2000, TC/PS
$0/ESM/(15 moi%)DSPE-PEG 2000, TC/PS-$0/ESMI(10 mol%)DSPE-PEG 5000,
and TC/PS-$0/ESM/(10 mol%)DSPE-4-armPEG. Elimination profiles of the
emulsions from blood are shown in Figure 14A. Comparable to the study in mice
bearing B 16 tumors, the non-PEGylated ESM emulsion was quickly removed from
blood with less than 20% of the ID remaining in the circulation 2 h post injection.
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Also similar to the mice inoculated with B 16 melanoma, the emulsions containing 10
mol% PEG 2000 prolonged circulation time with about 40% of the ID stiil present in
the blood afier 2 h. Increasing the concentration of PEG 2000 to 15 mol% or
enhancing the length of the PEG chain to 5000 g/mol did flot further prolong blood
residence time. it is possible that at 10 mol% PEG 2000, the colloid reached its
optimum protection with PEG and any additional increase in concentration and chain
length would not enhance circulation time further. Previous studies by our group have
shown that at low PEG concentrations (less than 4 mol%), small increases in PEG
concentration or increasing chain length from 2000 to 5000 g/mol enhanced the
circulation time of lipid nanocapsules [40]. However, at 6 mol% and above, almost no
difference was observed with increasing PEG 2000 concentration [40, 45] or PEG
chain length (2000 to 5000 g/mol) [40]. Similarly, Liu et al. [37] observed that
increasing the concentration of PEG 2000 at the interface prolonged circulation time
until a plateau in blood concentration was reached afier approximately 5 mol%.
Although the amount of DSPE-PEG anchored to the droplet surface was not
quantified in our study, the lack of detection of micelles in the region of 3-10 nm by
dynamic light scattering suggests that most of the D$PE-PEG was indeed bound to
the droplets (data not shown).
Even though graffing density was high (10 mol%), droplets coated with
DSPE-4-armPEG did not circulate as long as the other single chain D$PE-PEG
derivatives (Figure 14A). The PEG chain lengths ofeach arm were probably too short
to provide sufficient protection against opsonization. Indeed, the number of repeating
ethylene oxide units was only 11 per arm for 4-armPEG (equivalent to about 500
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g/mol per arm) compared to 45 and 113 for PEG 2000 and PEG 5000, respectively.
Previous groups have shown that the circulation time of the carrier is strongly
dependent on PEG chain length [46, 47]. For example, Allen et al. [47] observed that
liposomes grafied with PEG 1900 and PEG 5000 prolonged the blood residence time
of the carrier, while liposomes coated with shorter chain PEG-lipid derivatives (i.e.
PEG 750 and PEG 120) were removed more quickly from the systemic circulation.
Enhanced circulation time of PEGylated emulsions in blood translated into
higher accumulation into C26 tumors (Figure 143). The distribution of emulsions
grafted with PEG 2000 or PEG 5000 into the tumor was between 7.4 and 10.6% ID/g
afier 12 h, while only 2.6 and 3.9% ID/g was detected in the tumor for plain and 4-
armPEG coated emulsions, respectively. Even though plain and 4-armPEG coated
emulsions extravasated less into C26 tumors, all emulsions displayed selectivity for
the tumor over the muscle. Indeed, no more than 1.1% ID/g was distributed to the
muscle (Figure 14B and C). Our results are in general agreement with those obtained
with stealth liposomes, whereby their accumulation into subcutaneously implanted
C26 colon adenocarcinoma after 1 and 16 h post i.v. injection was approximately 7
and 18% ID/g, respectively [4$]. These liposomes (- 90 nm in diameter) reached a
maximum accumulation of about 20% ID/g at the 24 h time point [4$].
Regardless of the similar circulation times of emulsions with 10 mol% PEG
2000, accumulation was greater in C26 tumors compared to B16 at all time points.
The greatest difference was detected at 12 h post injection, whereby the emulsion
exhibited a 5-fold greater accumulation into C26 tumors than B16 (Figure 13B and
figure 143). This observation may be explained by lower vascular permeability of
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the 316 tumor compared to C26. In addition to leaky vasculature, other factors such
as differences in blood vessel density, blow flow rate, and interstitial pressure in
different tumor types can affect particulate accumulation [8]. Our finding is contrary
to the results of Ishida et al. [49] who reported that 316 and C26 tumors showed
similar permeability to liposomes with mean diameters ranging from 60 to 400 nm.
The discrepancy between the two studies may be attributed to differences in vascular
permeability and tumor volume at the time of injection.
The uptake of the emulsions by different organs afier 2, 6 and 12 h post i.v.
injection is presented in figure 15. As expected, the emulsions distributed mainly to
the MPS organs, with the majority of the formulation accumulating in the liver. for
ail emulsions, accumulation into the lungs, heart and kidneys was low. The enhanced
blood levels ofemulsions with PEG 2000 (10 and 15 mol%) and PEG 5000 translated
into lower uptake by the liver. In contrast, the plain and 4-armPEG-coated emulsions
which were cleared from blood faster accumulated more in the liver.
Several studies have reported the ability of emulsions to enhance the
accumulation of anticancer agents into solid tumors compared to the free drug [5, 50,
51]. While other reports have shown a greater reduction in tumor volume over time
when drugs are encapsulated into long-circulating emulsions versus free drug [52-55].
However, despite the vast amount of literature on emulsions as drug carriers in cancer
therapy flot much work has been devoted to characterizing the accumulation of the
droplet itself into solid tumors. In this study, we clearly demonstrated that nanosized
PEGylated emulsions prepared with commonly used pharmaceutical excipients can
passively target neoplastic tissues. The degree of emulsion accumulation into the
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tumor was dependent on the PEG coating and tumor type, whereby C26 colon
adenocarcinoma was more permeable to the emulsions than B 16 melanoma. These
emulsions can potentially enhance the selectivity of lipophilic anticancer drugs
towards tumor tissues and increase their therapeutic index.
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PEG Mean PU! Tumor
content Diameter
(01%)b (nm)
TC/P$-80/HSPC - 113 0.27 B16-F10
TC/PS-80/ESM - 103 0.32 B16-f 10
TC/P$-$0/ESWD$PE-PEG 2000 10 107 0.25 B16-F10
TC/PS-80/ESM - 110 0.29 C26
TC/P$-80/E$WDSPE-PEG 2000 10 114 0.26 C26
TC/PS-80/ESMIDSPE-PEG 2000 15 103 0.23 C26
TC/PS-80/ESWDSPE-PEG 5000 10 121 0.21 C26
TC/PS-80/ESM!DSPE-4-armPEG 10 110 0.24 C26
The weight ratio of lipids except for DSPE-PEG was kept constant (TC/PS-$O/X = 5:3:1, w/w, where
X is either HSPC or ESM).
b Expressed as mol% of total surface components (exciuding TC).
Table 6: Properties of the lipid emulsions administered to mice bearing either B16-
f10 melanoma or C26 colon adenocarcinoma
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Figure 11: Surface pressure versus molecular area (A) and surface pressure versus
modulus of compressibility (B) plots of HSPC and ESM at the air/water interface.
Subphase conditions: PBS pH 7.4, 25°C.
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Figure 12: Surface pressure versus molecular area (A) and surface pressure versus
modulus ofcompressibility (B) plots ofPS-$0, HSPC/PS-80 (1:3, w/w) and ESM/PS
$0 (1:3, w/w) at the air/water interface. Subphase conditions: PB$ pH 7.4, 25°C.
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figure 13: Elimination profile of emulsions from blood (A) and distribution to B 16-
f10 melanoma (B) and muscle (C) afier i.v. injection in C57BL/6 mice. Each mouse
was administered 5.4 mg of lipids (excluding DSPE-PEG) in a 100-[.LL injection
volume. Mean + SD (n = 4-5 mice/group). TC/PS-80/HSPC (u), TC/P$-$0/ESM (s),
and TC/PS-$0/ESMI(10 mol%)DSPE-PEG 2000 (.). Statistically significant
differences between plain and PEGylated emulsions are indicated. *p < 0.05.
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Figure 14: Elimination profile of emulsions from blood (A) and distribution to C26
colon adenocarcinoma (B) and muscle (C) afier i.v. injection in Balb/C mice. Each
mouse was administered 5.4 mg of lipids (excluding DSPE-PEG) in a 100-jiL
injection volume. Mean + SD (n = 4-5 mice/group). TC/PS-$0/ESM ( ) and TC/PS
80/ESM/(10 mol%)DSPE-PEG 2000 (.), TC/PS-$0/ESM/(15 mol%)DSPE-PEG
2000 (), TC/P$-$0/ESM/(10 mol%) DSPE-PEG 5000 (n), TC/PS-80/ESM/(10
mol%)DSPE-4-armPEG (z). Statistically significant differences between plain and
PEGylated emulsions are indicated. p < 0.05.
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figure 15: Effect of DSPE-PEG derivatives on the tissue distribution of the emulsions
in Balb/C mice inoculated with C26 colon adenocarcinoma after 2 h (A), 6 h (B), and
12 h (C) post i.v. injection. Mean + SD (n = 4-5 mice/group). TC/PS-80/ESM ( ) and
TC/PS-80/ESM]( 10 mol%)DSPE-PEG 2000 (.), TC/PS-$0/ESM!( 15 mol%)D$PE
PEG 2000 (), TC/PS-80/ESM!(10 mol%) DSPE-PEG 5000 (n), TCIPS-8OÏESM/(10
mol%)DSPE-4-armPEG ().
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CHAPTER 4: DISCUSSION
10$
1. Formulation optimization
for emulsions to accumulate into neoplastic tissues by the EPR effect, the
droplets must be smaller than the pores of the tumor blood capillaries [1] and must
possess sufficiently long residence times in blood to extravasate progressively at the
tumor site over time [2]. The ability ofemulsions to evade the MPS and circulate long
afier intravenous (i.v.) injection depends largely on the hydrodynamic diameter ofthe
dispersed droplets and the physicochemical properties ofthe surface [3-5].
Our strategy to achieve long residence times in blood and accumulation into solid
tumors was to develop an emulsion with a unimodal size distribution centered on 100
nm that was co-emulsified with egg sphingomyelin (ESM). This lipid emulsifier was
selected since several previous studies have shown that ESM prolonged the systemic
circulation time of emulsions and liposomes [6-8]. The desired droplet size was
realized by varying emulsifying parameters such as formulation composition
(surfactant type, oil/surfactant ratio) and the energy input for droplet size reduction
(sonication duration and intensity). This section describes the development of a nano
sized emulsion formulation that would later be coated with various 1 ,2-distearoyl-sn-
glycero-3 -phosphatidylethanolamine-poly(ethylene glycol) derivatives (DSPE-PEG)
including DSPE-PEG 2000, DSPE-PEG 5000, and DSPE-4-armPEG, and evaluated
in vivo for their ability to prolong circulation time and accumulate into solid tumors.
1.1. Emulsion composition
Formulation optimization began by screening through various synthetic
surfactants to identify the ones which were most suitable to emulsify tricaprylin tIC)
with E$M. This initial screening study was performed at various sonication intensities
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and durations, while the amount of ESM and TC was kept constant. The influence of
synthetic surfactant type was evaluated in a system composed of TC/E$M/X (5:1:3,
w/w), where X was either poloxamer 18$, span 40, sodium deoxycholate, sodium
cholate, sodium glycocholate or polysorbate 80 (PS-80). The emulsions were
prepared and characterized following the protocol described in Appendix I. From this
study, PS-80 had the best emulsifying properties since these emulsions had superior
physical stability under certain sonication conditions. Consequently, PS-80 was used
in future optimization studies.
Following these experiments, the oil/surfactant ratio and PS-80/ESM ratio were
varied while maintaining constant sonication conditions (duration: 25 s, intensity:
medium (72-84 W)). Refer to Appendix II for the procedure used to prepare the
emulsions. The influence of emulsion composition on droplet diameter and PDI is
presented in Figure 16. As expected, smaller droplets were produced at lower
oil/surfactant ratio due to increased lowering of the interfacial ftee energy with higher
emulsifier content (figure 1 6A) [9]. On the other hand, at low oil/surfactant ratio PDI
values were larger, which is probably due to the formulation of small micelles as a
resuit of the relatively large quantity of surfactant (figure 1 6B). As oil/surfactant
ratio increased, PDI values diminished while droplet diameter became larger. The
formulation that provided the best compromise between mean diameter and PDI was
with an oil/surfactant ratio and PS-$0/E$M ratio of 1.25 and 3, respectively. With this
formulation (TC/PS-80/ESM = 5:3:1, w/w), droplet size and PDI was 145 nm and
0.29, respectively (Figure 16A and B).
0.8
0.6
>
4-
0
0
0 0.5 1 1.5 2 2.5 3
Figure 16: Influence of the proportions of TC, PS-80 and ESM on mean droplet
diameter (A) and size distribution (B) of the emulsion. Sonication conditions were
kept constant at medium intensity (72-84 W) for 25 s. The weight ratio ofPS-$0/ESM
was either 0.6 (u), 1 (o), 3 (Â) or 7 (A). The external phase was citrate buffer at pH 5.
(- - -) indicates the range of acceptable diameter and PDI.
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1.2. Sonication parameters
Sonication is a process which reduces globule size by inducing cavitations
through the mechanical vibrations generated by the sonicator probe. The collapse of
these vapor bubbles produces high energy shockwaves throughout the liquid mixture
which breaks up the droplets [10]. The influence of sonication parameters, such as
intensity and duration on droplet diameter and PDI was investigated, while the
proportion of TC/PS-80/ESM (5:3:1, w/w) was maintained constant. Refer to
Appendix II for the procedure used to prepare the emulsions. As anticipated, Figure
17 shows that increasing sonication time and intensity reduced emulsion droplet size
and PDI. This can be explained by the stronger mechanical vibrations induced by
increasing the power input, producing more powerful shock waves that could break
up the initial globules into smaller droplets [10].
$onication at medium (72-84 W) or medium-high (92-102 W) intensity
produced emulsions with comparable mean diameters. At these power inputs, droplet
size leveled-off at approximately 100 nm (figure 1 7A). PDI, on the other hand, could
be decreased further by sonicating at rnedium-high intensity for longer durations (60
and 120 s) (figure 1 7B). Eventually these emulsions may be interesting carriers for
hydrophobie anticancer drugs. To avoid possibly overheating the formulation with
high sonication intensity and duration, which could potentially degrade heat sensitive
drugs, the parameters chosen for the in vivo studies were 40 s at medium intensity.
These conditions were sufficient to produce an emulsion with a diameter of about 100
nm and acceptable polydispersity (<0.3).
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figure 17: Influence of sonication intensity and time on mean droplet size (A) and
size distribution (B). The proportion ofTC, PS-$0 and ESM was kept constant (5:3:1,
w/w). The extemal phase was 0.9% w/v NaC1 in water.
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2. Emulsion stability
Several promising formulations were stored at ambient conditions and
checked for physical stability over time. The emulsions were examined visuaily for
signs of phase separation such as creaming, sedimentation, and ou droplets. In
addition, droplet diameter was monitored over time by dynamic light scattering. The
stabiiity of several non-PEGylated emulsions is presented in Table 7. for ail
emulsions, size increased over time while PDI decreased. Several hypotheses are
proposed to explain the change in emulsion size over time. One hypothesis is that the
emulsions are physically unstable and are showing signs of destabilization. The
increase in droplet size may be an indication of coalescence (fusion of separate
droplets) due to insufficient electrostatic or steric forces to overcome the attractive
Van der Waals forces as two globules approach each other [11]. Electrostatic
stabiiization was minimal since the emulsions were prepared with non-ionic
emulsifiers. Alternatively, the polydispersity in dropiet size may have promoted
Ostwald ripening [12]. This destabilization process occurs when the smail droplets
transfer oil to the larger ones causing the big ones to grow while the small ones
sbrink. Another possibility is that the increase in size may be partially due to
microbial growth since the emulsions were flot sterilized prior to storage and no
preservatives were added to the formulation.
Visualiy the emulsions did not show any indications of physical instability
over two months. Signs of phase separation were observed afier 3 months and
obvious phase separation was observed afier 4 months.
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Table 7: Stability of several non-PEGylated emulsions over time
Day O I Month 2 Months
TC ESM PS-80 Sonication
(mg) (mg) (mg) time (s) Diameter PDI Diameter PDI Diameter PDI(nm) (nm) (nm)
100 20 60 25 139.1 0.37 191.4 0.11 220.9 0.08
100 20 60 35 128.6 0.28 172.1 0.10 212.0 0.06
145 20 60 25 177.9 0.26 263.3 0.25 216.8 0.07
145 20 60 35 165.4 0.26 206.9 0.19 215.8 0.11
145 60 60 25 173.1 0.29 238.6 0.19 246.5 0.17
145 60 60 35 147.8 0.26 200.3 0.14 225.1 0.14
The formulations were sonicated at medium intensity (72-$4 W)
Subphase: 0.9% (w/v) NaC1 in water
Emulsions composed of TC/PS-$O/ESM (5:3:1, w/w) were then incubated
with DSPE-PEG 2000 at various concentrations (0, 6, 10 and 15 mol%). The physical
stability of the emulsions was evaluated by monitoring changes in droplet size over
time (Table 8). $urprisingly, emulsions coated with PEG 2000 increased in size over
time similar to the non-PEGylated formulations (Table 7 and Table 8). It was
expected that the polymer chains grafled to the surface of the emulsion droplets
would provide physical stability through steric hindrance at high grafiing densities. A
possible explanation for this observation is that the appropriate combination of
surfactants to provide an efficient film at the interface was flot found. For instance,
the considerable difference in alkyl chain length between the surfactants (P$-$0 and
ESM) and those of the TC core may be an issue. In addition or altematively, the
increase in droplet size may be a result of microbial growth which could destabilize a
formulation prematurely.
115
Table 8: $tability ofthe PEGylated emulsions over time
DSPE-PEG Day O Day $
2000 content Diameter Diameter
(mol%) (nm) PDI (nm) PDI
0 144.8 0.34 155.2 0.17
6 141.6 0.32 169.1 0.18
10 149.5 0.33 164.0 0.23
15 144.1 0.32 179.2 0.22
The weight ratio of Iipids except DSPE-PEG 2000 was
5:3:1)
Sonication conditions: 40 s, medium intensity (72-84 W)
Subphase: Millipore water
Day 16 Day 2$
Diameter PDI Diameter PDI(nm) (nm)
164.7 0.11 178.0 0.10
162.4 0.15 194.7 0.11
183.9 0.15 178.6 0.15
188.2 0.15 199.2 0.15
kept constant (TC/PS-$0/ESM =
3. Compression isotherms
following the initial optimization study, ESM monolayers were characterized
at the air/water interface in PBS buffer (pH 7.4) and compared to a high phase
transition phospholipid (hydrogenated soybean phosphatidylcholine, HSPC) using the
Langmuir balance technique (refer to figure 1 lA and B in Chapter 3). These lipids
were characterized alone and in the presence of PS-80 for monolayer compressibility,
molecular conformation and fluidity. for the pure lipids, two important differences
were identified between the molecules. f irst, ESM formed a more compressible film
than HSPC as indicated by the more gradual increase in surface pressure as molecular
area decreased. The disparity in monolayer compressibility between the two
molecules may be attributed to differences in chain unsaturation. The acyl chains of
HSPC are completely saturated, while a double bond is present in ESM between
carbons 4 and 5 of the sphingosine backbone. The unsaturation in E$M might
produce a more fluid and disordered monolayer than HSPC. The second difference
observed between the molecules is that ESM could form a more densely packed film
above about 25 mN/m (see figure 1 lA in Chapter 3). The ability of E$M to form a
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tighter monolayer can be explained by its greater hydrogen bonding capacity
compared to phosphatidylcholines (PCs) due to the presence of an amide and
hydroxyl group in the molecular structure. The intra- and intermolecular hydrogen
bonding within and between ESM molecules may decrease head group hydration,
which could permit the molecules to pack more tightly. Previous studies have
reported that ESM head groups are less hydrated in monolayers and bilayers
compared to PCs, such as DPPC and egg PC [13, 14].
The fluidity and compressibility of both HSPC and E$M monolayers
increased considerably when mixed with PS-$O (see figure 12A and B in Chapter 3).
Over the range of molecular areas investigated, both HSPC/PS-80 (1:3, w/w) and
ESMJP$-80 (1:3, w/w) displayed almost identical compressibilities. However,
compared to pure PS-$O and HSPC/P$-8O, ESMIPS-8O formed a more densely
packed film at the air/water interface (the mixture occupied the smallest area). A
possible explanation for this observation is a reduction in hydration of the polar head
group due to the formation of intra- and intermolecular hydrogen bonds with ESM
and maybe also with PS-8O. The lower head group hydration could permit denser
packing of the molecules. The tighter molecular packing of ESM/PS-80 monolayers
may potentially enhance monolayer stability in plasma and prolong the systemic
circulation time of an emulsion.
4. Biodistribution studies
Based on the resuits of the monolayer experiments, we compared ESM versus
HSPC emulsions in vivo. The emulsions were prepared with the same proportions of
oil and surfactant (TC/PS-8O/HSPC or ESM = 5:3:1, w/w) and sonicated at the same
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conditions (medium intensity, 40 s). Ibis basic formulation was chosen for the
biodistribution experiments based on the optimization studies, whereby emulsions of
100 nm with acceptable PDI values (<0.3) were obtained under these conditions.
$ubstituting HSPC for E$M did flot considerably alter the size of the emulsion (refer
to Table 6 in Chapter 3). These emulsions were administered intravenously via the
subclavian vein to mice inoculated with B16 melanoma. Afier i.v. injection no
significant difference was observed between ESM and HSPC emulsions (p> 0.05)
(Figure 13A, Chapter 3). Although a statistical significance could flot be
demonstrated, the % ID at the 2 h tirne point was slightly higher for the emulsion
containing ESM, which may be attributed to a tighter monolayer at the interface.
Following these experiments, the influence of PEG concentration, chain
length, and structure in prolonging systemic circulation time was investigated. This
was done by coating emulsions composed of TC/PS-$0/ESM (5:3:1, w/w) with
various DSPE-PEG derivatives including DSPE-PEG 2000, DSPE-PEG 5000 and
DSPE-N-[pentaerythritol polyoxyethylene) glutarylJ (DSPE-4-armPEG) (PEG MW
2000). Droplet diameter was maintained constant between 100 — 120 nm such that
blood residence time was dependent only on the physicochemical properties of the
carrier (refer to Table 6 in Chapter 3). As expected, inserting DSPE-PEG 2000 or
PEG 5000 into the emulsion interface at high grafting densities (10 or 15 mol%)
significantly prolonged circulation time (p < 0.05) (Figure 14A, Chapter 3). Despite
the 2000 MW PEG segment and high graffing density (10 mol%), emulsions coated
with DSPE-4-armPEG did flot exhibit higher residence times in blood compared to
plain, non-PEGylated emulsions. The inability of DSPE-4armPEG to extent
11$
circulation time is probably due to the lower molecular weight PEG segment per arm
(500 g/mol) compared to single-chain PEG 2000 and PEG 5000. Previous groups
have shown that the circulation time of the carrier was lower when coated with
shorter PEG chains (i.e. PEG 750 and PEG 120) compared to PEG 1900, 2000 and
5000 [15, 16].
Enhanced circulation time of emulsions grafted with PEG 2000 or 5000
translated into higher accumulation into C26 tumors but flot into B16 (figure 13B and
figure 143, Chapter 3). The lower uptake of emulsions by B16 melanoma may be
due to several factors including lower vascular permeability and differences in blood
vesse! density, blow flow rate, and interstitial pressure in different tumor types [17].
The uptake of the emulsions by the organs at different time points is presented
in figure 15 in Chapter 3. The emulsions were taken up mainly by the liver followed
by the spleen. As anticipated, the emulsions which had higher blood residence times
accumulated less in the liver.
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CHAPTER 5: CONCLUSION
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Oil-in-water submicrometer emulsions are promising vehicles for the delivery
of highly lipophilic anticancer drugs to neoplastic tissues. The main advantages of
emulsions over other colloidal dmg delivery systems include the potential to
solubilize high quantities of lipophulic compounds, relative ease of manufacture at an
industrial scale, and reasonable stability under storage conditions. In this study, we
clearly demonstrated that nanosized PEGylated emulsions prepared with commonly
used pharmaceutical excipients can passively target solid tumors. The efficacy of
emulsion uptake into the tumor was dependent on the physicochemical properties of
the surface and the tumor model. These emulsions can potentially enhance the
selectivity of lipophilic anticancer drugs towards tumor tissues, resulting in reduced
systemic toxicities and increased therapeutic index, provided that the encapsulated
cargo remains associated with the vector afier i.v. injection. These resuits will
undoubtedly improve the understanding of ernulsion accumulation into solid tumors.
Future work will involve enhancing the physical stability of the emulsions in
storage. Ideally, the formulation should be physically and chemically stable for at
least one year. Moreover, the ability of the emulsions to incorporate hydrophobie
anticancer drugs ought to be investigated, followed by an assessment of drug
retention in vitro and in vivo. In general, molecules with high lipophilicities (log P>
9) are retained better within the emulsion in the presence of biological fluids [1, 2].
Thus, in order to achieve high dnig levels at the tumor site it is recommended to load
these emulsions with highly lipophilic compounds (log P> 9).
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The ongoing advancement in delivery systems for anticancer drugs will
eventually lead to safer and more tolerated therapies. Hopefully, this study wilI
enhance interest in developing emulsions as carriers for antineoplastic agents.
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APPENDIX I
The emulsions were prepared by first mixing ail components (ou, lipid
surfactant, and synthetic surfactant) under gentie agitation (stirring bar) above the
phase transition temperature of ESM for 5-10 min. The dispersing phase (0.9% w/v
NaC1 in water) was then added to the premix and the formulation was heated/mixed at
55°C for an additional 20 to 60 min. Afler the addition of extemal phase the dispersed
phase represented 9% (w/v) of the emulsion. The formulations were then sonicated in
batches of 1 mL in a 1.5 mL eppendorf at various intensities and durations on pulse
mode (pulse every 2 s for 0.2 s). After sonication, a sample of formulation was taken
and measured for mean hydrodynamic diameter by dynamic light scattering using a
Malvern Autosizer (Malvem Instruments Ltd, Maïvem, UK) at 25°C and a fixed
angle of 90°. Each formulation was then extruded several times (- 11 times) through a
100 - 200 nm filter using a 1 mL hand-held extruder. Following extrusion a second
size measurement was made for each formulation. The emulsions were stored at
ambient conditions and monitored visually for signs of phase separation such as
creaming, sedimentation and ou droplets.
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APPENifiX II
The emulsions were prepared by first mixing ail components (TC, P$-80, and
E$M) under gentie agitation (stirring bar) above the phase transition temperature of
ESM for 5-10 min. The dispersing phase (0.9% w/v NaC1 in water, citrate buffer at
pH 5 or Millipore water) was then added to the premix and the formulation was
heated!mixed at 55°C for an additional 20 to 45 min. After the addition of extemal
phase the dispersed phase represented between 6 to 14% (w/v) of the emulsion. The
formulations were removed from the heat and vortexed for 2 min. The emulsions
were then sonicated in batches of 1 mL in a 1.5 mL eppendorf at medium intensity for
25 to 40 s on pulse mode (pulse every 2 s for 0.2 s). Size measurements were made by
dynamic light scattering using a Malvem Autosizer (Malvem Instruments Ltd,
Malvem, UK) at 25°C and a fixed angle of 90°.
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